   
 
 A5324  
 
 
A Randomized, Double -Blinded, P lacebo -Controlled Trial Comparing 
Antiretroviral Intensification  with Maraviroc and Dolutegravir  with N o 
Intensification or Intensification with Dolutegravir  Alone for the Treatment of 
Cognitive Impairment in HIV 
  
A Multicenter  Trial of the AIDS Clinical Trials Group (ACTG)  
  
Sponsored by:  
The National Institute of Allergy  
and Infectious Diseases 
 
 
Industry  Support Provided by: 
ViiV Healthcare Ltd.  
 
 
 IND# 126,854  
 
 
The ACTG Neurology   
Collaborative  Science Group:    S cott Letendre, MD , Chair  
  Protocol Chair :  Kevin Robertson, PhD  
   
Protocol Co- Chair : Serena Spudich, MD  
 
Protocol Vice-Chair :  Scott Letendre, MD   
  
DAIDS Clinical Representative:    Beverly L. Alston -Smith, MD  
 Clinical Trials Specialist : Jhoanna C. Roa , MD  
   
  
 
 
 Final  Version 2.0 
August  25, 2017  
 
 
A5324 
Final Version 2.0  
  08/25/17  
 
 A Randomized, Double -Blinded, Placebo- Controlled Trial Comparing 
Antiretroviral Intensification with Maraviroc and Dolutegravir with No 
Intensification or Intensification with Dolutegravir Alone for the Tre atment of 
Cognitive Impairment in HIV  
 
SIGNATURE PAGE  
 
 
I will conduct the study in accordance with the provisions of this protocol and all 
applicable protocol -related documents. I agree to conduct this study in compliance with 
United States (US) Health and Human Service regulations (45 CFR 46); applicable U.S. Food and Drug Administration regulations; standards of the International Conference on 
Harmonization Guideline for Good Clinical Practice (E6); Institutional Review 
Board/Ethics Committee determinations; all applicable in- country, state, and local laws 
and regulations; and other applicable requirements (e.g., US National Institutes of Health, Division of AIDS) and institutional policies.  
  
 
 
 
Principal Investigator: _______________________________________________ Print/Type  
  
 
  
Signed: ___________________________________ Date: _____________ 
Name/Title  
  
 
A5324 
Final Version 2.0  
  08/25/17  
 
  CONTENTS  Page 
 SITES PARTICIPATING IN THE STUDY .................................................................................... 5 
PROTOCOL TEAM ROSTER  ..................................................................................................... 6 
STUDY MANAGEMENT  ........................................................................................................... 10 
GLOSSARY OF PROTOCOL -SPECIFIC TERMS  ..................................................................... 13 
SCHEMA  .................................................................................................................................. 14 
1.0 HYPOTHESES AND STUDY OBJECTI VES.................................................................. 15 
1.1 Hypotheses  ........................................................................................................ 15 
1.2 Primary Objectives  ............................................................................................. 15 
1.3 Secondary Objectives  ........................................................................................ 15 
2.0 INTRODUCTION  ........................................................................................................... 16 
2.1 Background/Rationale ........................................................................................ 16 
3.0 STUDY DESIGN  ........................................................................................................... 24 
4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS  ............................................... 25 
4.1 Inclusion Criteria  ................................................................................................ 25 
4.2 Exclusion Criteria ............................................................................................... 27 
4.3 Study Enrollment Procedures ............................................................................. 29 
4.4 Coenrollment Guidelines  .................................................................................... 30 
5.0 STUDY TREATMENT  ................................................................................................... 31 
5.1 Regimens, Administration, and Duration  ............................................................ 31 
5.2 Study Product Formulation and Preparation ....................................................... 32 
5.3 Pharmacy: Product Supply, Distribution, and Accountability  .............................. 33 
5.4 Concomitant Medications  ................................................................................... 33 
6.0 CLINICAL AND LABORATORY EVALUATIONS  ........................................................... 34 
6.1 Schedule of Evaluations ................................................................................... 34 
6. 
2 Timing of Evaluations  ......................................................................................... 36 
6.3 Instructions for Evaluations  ................................................................................ 37 
7.0 CLINICAL MANAGEMENT ISSUES  .............................................................................. 46 
7.1 Toxicity  Management  ......................................................................................... 46 
7.2 Additional Considerations for Participants  Infected with Hepatitis B 
Virus (HBV)  ........................................................................................................ 51 
7.3 Pregnancy .......................................................................................................... 51 
7.4 Breastfeeding ..................................................................................................... 52 
7.5 Unblinding  .......................................................................................................... 52 
7.6 Antiretroviral Therapy Changes ...................................................................... 52 
 A5324 
Final Version 2.0  
 CONTENTS (Cont'd)   08/25/17  
 
 Page 
 
8.0 CRITERIA FOR DISCONTINUATION  ........................................................................... 52 
8.1 Premature Treatment Discontinuation  ................................................................ 52 
8.2 Premature Study Discontinuation ....................................................................... 53 
9.0 STATISTICAL CONSIDERATIONS ............................................................................... 53 
9.1 General Design Issues  ....................................................................................... 53 
9.2 Outcome Measures  ..........................................................................................  54 
9.3 Randomization and Stratification ........................................................................ 55 
9.4 Sample Size and Accrual  ................................................................................... 56 
9.5 Monitoring  .......................................................................................................... 58 
9.6 Analyses  ............................................................................................................ 59 
10.0  PHARMACOLOGY PLAN  .............................................................................................. 61 
10.1  Pharmacology Objectives  .................................................................................. 61 
10.2  Pharmacology Study Design .............................................................................. 62 
10.3  Primary and Secondary Data, Modeling, and Data Analysis  .............................. 63 
10.4  Anticipated Outcomes  ........................................................................................ 63 
11.0  DATA COLLECTION AND MONITORING AND ADVERSE EVENT REPORTING  ........ 63 
11.1  Records to Be Kept  ............................................................................................  63 
11.2  Role of Data Management  ................................................................................. 63 
11.3  Clinical Site Monitoring and Record Availability  .................................................. 64 
11.4  Expedited Adverse Event Reporting to DAIDS  ................................................... 64 
12.0  PARTICIPANTS  ............................................................................................................ 65 
12.1  Institutional Review Board (IRB) Review and Informed Consent  ........................ 65 
12.2  Participant  Confidentiality  ................................................................................. 66 
12.3  Study Discontinuation ........................................................................................ 66 
13.0  P UBLICATION OF RESEARCH FINDINGS  .................................................................. 66 
14.0  BIOHAZARD CONTAINMENT  ...................................................................................... 66 
15.0  REFERENCES  .............................................................................................................. 67 
APPENDIX I:  SAMPLE INFORMED CONSENT  
 5 A5324 
Final Version 2.0  
  08/25/17  
 
 SITES P ARTICIPATING IN THE STUDY  
 
A5324 is a multicenter study and will be opened only at US and select non- US AIDS  Clinical 
Trials Group (ACTG) clinical research sites (CRSs). Refer to the Site tab on the protocol’s 
web page on the ACTG Member website for the list of eligible non -US CRS s.
 6 A5324 
Final Version 2.0  
  08/25/17  
 
 PROTOCOL TEAM ROSTER  
 
Chair 
Kevin Robertson, PhD  
Department of Neurology  
School of Medicine 
University of North Carolina  
2127 Physicians Office Building  
170 Manning Drive  
Chapel Hill, NC 27599 -7025 
Phone: 919- 966-5549  
FAX: 919-9 66-2922  
E-Mail: kevinr@neurology.unc.edu  
 
Co-Chair  
Serena Spudich, MD  
Neurology  
Yale University School of Medicine  
Cornell CRS  
P.O. Box 208018  
15 York Street  
New Haven , CT 06520  
Phone: 650- 400-1222  
FAX: 203-737-2704  
E-Mail: serena.spudich@yale.edu  
 
Vice Chair  
Scott Letendre, MD  
UCSD Antiviral Research Center  
220 Dickinson Street, Suite A  
San Diego, CA 92103  
Phone: 619- 543-8080  
FAX: 619-298-0177  
E-Mail: sletendre@ucsd.edu  
 
DAIDS Clinical Representative  
Beverly L. Alston -Smith, MD  
Complications and Co -Infectious 
Research Branch  
TRP, DAIDS, NIAID, NIH  
5601 Fishers Lane, 9F50 
Rockville, MD  20852  
Phone:  301-435-3773  
FAX:  301-480-4522  
E-Mail:  balston@niaid.nih.gov   Clinical Trials Specialist  
Jhoanna C. Roa, MD  
ACTG Network Coordinating Center  
Social & Scientific Systems, Inc.  
8757 Georgia Avenue, 12th Floor  
Silver Spring, MD 20910 -3714  
Phone: 301- 628-3196  
FAX: 301-628-3302  
E-Mail: jroa@s -3.com  
 
Statistician s 
Huichao Chen, PhD  
Statistical & Data Analysis Center  
Harvard School of Public Health  
FXB Building, Room 607  
651 Huntington Avenue  
Boston, MA 02115- 6017  
Phone: 617- 432-0040  
FAX: 617-432-2843  
E-Mail: hchen@sdac.harvard.edu   
 
Ashley McKhann, MS  
Statistical & Data Analysis Center  
Harvard School of Public Health  
FXB Building, Room 604B  
651 Huntington Avenue  
Boston, MA 02115 -6017 
Phone:  617-432-7986  
FAX:  617-432-2843  
E-Mail:  amckhann@sdac.harvard.edu  
 
Data Manager  
Dave Rusin, MT (ASCP), CCRP  
Frontier Science & Technology Research Foundation, Inc.  
4033 Maple Road  
Amherst, NY  14226- 1056 
Phone: 716- 834-0900 x7333  
FAX: 716-834-8432  
E-Mail: rusin.david@fstrf.org
 
 
 7 A5324 
Final Version 2.0  
 PROTOCOL TEAM ROSTER (Cont ’d) 08/25/17  
 
DAIDS Pharmacist  
Nayri Khairalla, PharmD, BS  
Pharmaceutical Affairs Branch 
DAIDS, NIAID, NIH  
5601 Fishers Lane, 9D 35 
Rockville, MD 20852  
Phone:  301-761-6659  
FAX:  240-627-3112  
E-Mail:  nayri.khairalla@nih.gov    
 
Immunologist  
Peter Hunt, MD  
University of California  
San Francisco AIDS CRS  
SFGH Building 80, Ward 84  
995 Potrero Avenue  
San Francisco, CA 94110 Phone: 415- 476-4082 Ext. 345  
FAX: 415-476-6953  
E-Mail: phunt@php.ucsf.edu
 
 
Pharmacologists  
Qing Ma, PhD  
NYS Center of Excellence in Bioinformatics 
and Life Sciences 
University of Buffalo  
701 Ellicott Street  
Buffalo, NY 14203  
Phone: 716-881-7500  
FAX: 716-645-2886  
E-Mail: qingma@buffalo.edu  
 Gene Morse, PharmD 
Translational Pharmacology Research Core  
NYS Center of Excellence in Bioinformatics 
and Life Sciences  
University of Buffalo  
701 Ellicott Street  
Buffalo, NY 14203  
Phone: 716- 881-7464  
FAX: 716-645-3635  
E-Mail: emorse@buffalo.edu
 
 Virologist  
Robert W. Coombs, MD, PhD  
University of Wa shington Retrovirology 
Laboratory  
Research and Training Building, 7th floor  
325 9th Avenue  
Seattle, WA  98104  
Phone: 206- 897-5205  
FAX:  206-897-5203  
E-Mail:  bcoombs@u.washington.edu  
 
Investigators  
Thomas Ca mpbell, MD  
University of Colorado Hospital CRS  
Division of Infectious Diseases  
Mail Stop B -168, Room P15- 11001 
12700 E. 19th Avenue  
Aurora, CO 80045  
Phone: 303-724-4929  
FAX: 303-724-4926  
E-Mail: thomas.campbell@ucdenver.edu  
 Eric Daar, MD  
Los Angeles Biomedical Research Institute  
Harbor -UCLA Medical Center CRS 
1124 West Carson Street, Building N- 24 
Torrance, CA 90502  
Phone: 310-222-2467  
FAX: 310-533-0447  
E-Mail: edaar@labiomed.org
 
 
Christina Marra, MD  
Department of Neurology  
University of Washington  Harborview Medical Center  
Box 359775  
325 9th Avenue  
Seattle, WA 98104- 2499  
Phone: 206- 897-5400  
FAX: 206-897-5401  
E-Mail: cmarra@u.washington.edu
 
 
 8 A5324 
Final Version 2.0  
 PROTOCOL TEAM ROSTER (Cont ’d) 08/25/17  
 
Investigators (cont’d)  
Aaron McMurtray, MD, PhD  
Department of Neurology  
Harbor -UCLA Medical Center  
1000 West Carson Street  
Torrance, CA 90509  
Phone: 310- 222-3897  
E-Mail:  amcmurtray @hotmail.com  
 
NIMH Representative  
Deborah Ann Colosi, PhD Division of AIDS Research  
National Institute of Mental Health/NIH  
6001 Executive Boulevard NSC 6115D -9619 
Bethesda, MD 20892  
Phone: 301-443-8542  
E-Mail: Deborah.Colosi@nih.gov
 
 
NINDS Representative  
May Wong, PhD  NeuroAIDS & Infectious Diseases  
National Institute of Neurological Disorders and Stroke/NIH  
6001 Executive Boulevard 
Neuroscience Center, Room 2113  
Bethesda, MD   20892 -9521  
Phone: 301- 496-1 431  
FAX: 301-402-2060  
E-Mail:  wongm@ninds.nih.gov
  
 
Field Representative  
Baiba Berzins, MPH  
Division of Infectious Diseases  
Feinberg School of Medicine Northwestern University  
645 N. Michigan Avenue, Suite 900  
Chicago, IL 60611  
Phone: 312- 695-5012  
FAX: 312-695-5088  
E-Mail: baiba@northwestern.edu
 
 Laboratory Technologist  
Robin DiFrancesco, MT (ASCP), MBA  
Translational Pharmacology Research Core  
NYS Center of Excellence in Bioinformatics and Life Sciences  
701 Ellicott Street  
Buffalo, NY 14203  
Phone:  716-881-7465   
FAX:  716-849-6890  
E-Mail:  rda@buffalo.edu
  
 
Community Scientific Subcommittee (CSS) 
Representative 
Larry N. Lyle, DO, MS  
University of California, San Diego 
AntiViral Research Center CRS  
3719 Louisiana Street  
San Diego, CA 92104- 3212 
Phone:  619-368-3408  
FAX: 619-299-4775  
E-Mail: lyledo2004@yahoo.com   
 
International Site Specialist  
Mary Allegra Cermak, MFA  
ACTG Network Coordinating Center  
Social & Scientific Systems, Inc.  
8757 Georgia Avenue, 12th Floor  
Silver Spring, MD 20910- 3714  
Phone: 301- 628-3312  
FAX: 301-628-3302  
E-Mail:  acermak@s- 3.com   
 
Industry Representative  
Belinda Ha, PhD  
ViiVHealthcare Ltd.  
Five Moore Drive  
Research Triangle Park, NC 27709 Phone: 919- 483-8284  
FAX: 919-483-8999  
E-Mail: belinda.f.ha@gsk.com
 
 
 9 A5324 
Final Version 2.0  
 PROTOCOL TEAM ROSTER (Cont ’d) 08/25/17  
 
Laboratory Data Manager  
Andee Fox, MPH  
Frontier Science & Technology Research 
Foundation  
4033 Maple Road  
Amherst, NY 14226  
Phone:  716-834-0900 Ext. 7276  
E-Mail:  fox@fstrf.org  
  
  
 
 
 
  
 10 A5324 
Final Version 2.0  
  08/25/17  
 
 STUDY MANAGEMENT  
 All general questions concerning this protocol should be sent to actg.teamA5324@fstrf.org
 via 
e-mail. The appropriate team member will respond with a "cc" to actg.teamA 5324@fstrf.org. A 
response should generally be received within 24 hours (Monday -Friday) . 
 
Protocol E-mail Group  
Sites should contact the User  Support Group at the Data Management Center (DMC) as soon 
as possible to have the relevant personnel at the site added to the actg.protA 5324 e- mail group. 
Include the protocol number in the e -mail subj ect line.  
• Send an e- mail message to actg.user.support@fstrf.org   
 
Clinical Management  
For questions concerning entry criteria, toxicity management, concomitant medications, and 
coenrollment, contact the Core team .  
• Send an e- mail message to actg.coreA5324@fstrf.org . Include the protocol number, 
patient identification number (PID), and a brief relevant history. 
 
Immunology  
For questions specifically related to immunologic  tests, contact the  protocol immunologist . Send 
an e- mail message to actg.coreA5324@fstrf.org  (ATTN: Peter Hunt ). 
 
Pharmacology  
For questions specifically related to pharmacologic laboratory tests, contact the protocol pharmacologists. Send an e- mail message to actg.coreA5324@fstrf.org
 (ATTN: Qing Ma and 
Gene Morse).  
 
Virology  
For questions specifically related  to virologic laboratory tests, contact the protocol virologist. 
Send an e- mail message to actg.coreA5324@fstrf.org  (ATTN: Robert Coombs).  
 
Data Management  
• For nonclinical questions about transfers, inclusion /exclusion criteria, case report forms 
(CRF), the CRF schedule of events, randomization/registration, and other data 
management issues, contact the data manager. CRFs can be downloaded from the 
FSTRF website at www.frontierscience.org .  
• For transfers, reference the Study Participant  Transfer SOP 11 9, and contact Dave 
Rusin  (rusin.david@fstrf.org)  directly.  
• For other questions, send an e -mail message to  actg.coreA5324@fstrf.org  (ATTN: 
Dave Rusin ).  
• Include the protocol number, PID, and a detailed question.  
 
Randomization/ Participant  Registration  
For randomization/ participant  registration  questions or problems and study identification 
number SID lists .  
• Send an e- mail message to rando.support@fstrf.org  or call the DMC Randomization 
Desk at 716- 834-0900, extension 7301.   
 11 A5324 
Final Version 2.0  
 STUDY MANAGEMENT (Cont’d)  08/25/17  
 
 
Computer and Screen Problems   
Contact the SDAC/DMC pr ogrammers.  
• Send an e- mail message to  actg.user.support@fstrf.org  or call 716- 834-0900, 
extension 7302. 
 
Protocol Document Questions  
For questions concerning the protocol document, contact the clinical trials specialist. Send an e -
mail message to actg.coreA5324@fstrf.org  (ATTN: Jhoanna Roa).  
 
Copies of the Protocol  
To request a hard copy of the protocol, send  an email  message to  ACTGNCC@s -3.com  
(ATTN: Diane Delgado). Electronic copies can be downloaded from the ACTG website at 
https://www.actgnetwork.org . 
 
Product  Package Inserts and/or Investigator Brochures  
To request copies of product  package inserts or investigator brochures, contact the DAIDS 
Regulatory Support  Center (R SC) at RIC@tech -res.com  or call 301 -897-1708. 
 
Protocol Registration  
For protocol registration questions , send an e- mail message to Protocol@tech- res.com  or call 
301-897-1707 .  
 
Protocol Activation  
For questions related to protocol activation, contact the clinical trials specialist  at 
jroa@s -3.com or ACTG Site Coordination Group at actgsitecoordination@s -3.com .  
 
Study Product  
For questions or problems regarding study product , dose, supplies, records, and returns, call 
Nayri Khairalla, protocol pharmacist, at 301 -761-6659.  
 
Study Drug Orders  
Call the Clinical Research Products Management Center (CRPMC) at 301 -294-0741.  
 
IND (Investigational New Drug) Number or Questions  
For any questions related to the IND submission, contact the DAIDS RSC at  
Regulatory@tech -res.com  or call 301- 897-1706.  
 
Expedited Adverse Event  (EAE) Reporting/Questions   
Contact DAIDS through the R SC Safety Office at DAIDSRSCSafe tyOffice@tech -res.com  or call 
1-800-537-9979 or 301-897-1709; or fax 1- 800-275-7619 or 301 -897-1710.  
 
Telephone Calls  
Sites are responsible for documenting any phone calls made to A5 324 team members.  
• Send an e- mail to actg.coreA5324@fstrf.org . 
 
 12 A5324 
Final Version 2.0  
 STUDY MANAGEMENT (Cont’d)  08/25/17  
 
Protocol -Specific Web Page 
Additional information about management of the protocol can be found on the protocol -specific 
web page (PSWP) . 
13 A5324 
Final Version 2.0  
  08/25/17  
 
GLOSSARY OF PROTOCOL -SPECIFIC TERMS  
 
ADL  activities of daily living  
ANI   asymptomatic neurocognitive impairment  
BDI-II  Beck Depression Inventory II  
BMI  body mass index  
CLIA   Clinical Laboratory Improvement Amendments  
CPE  CNS Penetration Effectiveness  
CSF  cerebrospinal fluid 
DTG   dolutegravir or Tivicay  
HAD   HIV-associated dem entia  
HAND   HIV-associated neurocognitive disorder  
HTLV -1 human T -lymphotropic virus type 1  
HVLT -R Hopkins Verbal Learning Test Revised  
IHDS   International HIV Dementia Scale  
IP-10  interferon gamma- induced protein 10  
LAR  legally authorized representativ e 
LP  lumbar puncture  
LPS  lipopolysaccharide  
LTR  long terminal repeat sequences  
MCP -1  monocyte chemoattractant protein-1 
MND   mild neurocognitive disorder  
MVC   maraviroc or Selzentry  
NFL  n eurofilament light chain  
PHQ -9  Patient Health Questionnaire-9 
PML  progressive multifocal leukoencephalopathy  
RLS  resource limited settings  
RPR   rapid plasma reagin  
TB  tuberculosis  
TBI  traumatic brain injury  
VF  virologic failure  
VDRL   venereal disease research laboratory  
WAT   Word Accentuation Test  
WRAT -4 Wide Range Achievement Test 4    
14 A5324 
Final Version 2.0  
  08/25/17  
 
SCHEMA  
 
 
A5324 
 
A Randomized, Double- Blinded, Placebo- Controlled Trial Comparing Antiretroviral 
Intensification with Maraviroc and Dolutegravir  with No Intensification or Intensification with 
Dolutegravir  Alone for the Treatment of Cognitive Impairment in HIV  
  
DESIGN  This is a phase IV randomized, double- blinded, placebo- controlled study 
to assess the efficacy of adding m araviroc (MVC) and dolutegravir (DTG) 
to the current antiretroviral therapy ( ART)  of HIV -infected individuals with 
undetectable (<50 copies/mL) plasma HIV -1 RNA, who have mild to 
moderate neurocognitive impairment, with a primary outcome of 
improvement in neurocognitive performance.  
  
DURATION 96 weeks  
  
SAMPLE SIZE  186 participants  
 
 
POPULATION   Participants  will have HIV -associated neurocognitive disorder (HAND) as 
defined by the Frascati criteria,  plasma HIV -1 RNA <50 copies/mL within 
90 days prior to entry , and no more than one plasma HIV -1 RNA ≥50 and 
<200 copies/mL in the past 6 months prior to entry with a subsequent plasma HIV -1 RNA <50 copies/mL, and on stable ART for at least 6  
months prior to entry with no plans to change treatment.  
  
STRATIFICATION   Participants  will be r andomized in a stratified manner. Stratification 
variables will be CD4+ nadir (≤100 vs. >100 cells/mm3), and HAND 
severity (asymptomatic neurocognitive impairment [ANI]  vs. mild 
neurocognitive disorder [MND]  / HIV-associ ated dementia [HAD] ). 
 
 
REGIMEN  At entry participants  will be randomized to one of the following:  
 
Arm A: Add to their existing ART: placebo for MVC  and p lacebo for DTG  
 Arm B: Add to their existing ART: DTG and placebo for MVC   
 Arm C : Add to their existing ART:  MVC an d DTG  
 
 
15 A5324 
Final Version 2.0  
  08/25/17  
 
1.0 HYPOTHESE S AND STUDY OBJECTIVES 
 
1.1 Hypothes es 
 
1.1.1  Primary  
 In HIV -1-infected participants with suppressed plasma viremia and at least mild 
neurocognitive impairment, improved neurocognition and increased functional 
capacity over 48 weeks will be seen with addition of maraviroc (MVC) plus  
dolutegravir (DTG) (Arm C) compared to DTG only (Arm B) and compared to placebos (Arm A). Addition of DTG only (Arm B) compared to placebos (Arm A) 
will result in improved neurocognition over 48 weeks and increased func tional 
capacity.   
 1.1.2  Secondary  
 Changes in peripheral blood and cerebrospinal fluid ( CSF) biomarkers will 
parallel improvement in neurocognitive performance following addition of DTG 
alone or MVC  and DTG .  
 
1.2 Primary Objective s 
  
1.2.1  To determine whether intensification with MVC and DTG (Arm C)  will improve 
neurocognitive functioning at week 48 in participants who have at least mild 
neurocognitive impairment, are on a stable antiretroviral therapy (ART) regimen, and have plasma HIV- 1 RNA <50 copies/mL, over DTG  plus placebo for MVC  
(Arm B) and over placebo of both drugs ( Arm A) . 
 
1.2.2  To determine whether DTG with placebo for MVC (Arm B) will improve 
neurocognitive functioning at week 48 over placebo of both drugs (Arm A) . 
 1.3  Secondary Objectives  
 
1.3.1  To determine the safety and tolerability of MVC and DTG when added to a stable ART regimen. The safety and tolerability measures will include time to 
discontinuation of any study medication due to adverse events (AEs), proportion 
of Grade 3 or Grade 4 clinical AEs, proportion of Grade 3 or Grade 4 laboratory 
abnormalities, and summaries of all treatment- related AEs .  
 
1.3.2  To determine whether  intensification with MVC and DTG will improve 
neurocognit ive functioning at weeks 24, 72 , and 96. 
 
1.3.3  To determine whether functional status  improves at week 48 after intensification 
with MVC and DTG  (Arm  C) to a greater extent than when intensified with DTG 
and placebo for MVC  (Arm B) or placebo of both drugs  (Arm A). 
 
1.3.4  To assess the effect of adding MVC and DTG on biomarkers in peripheral 
blood and CSF. 
16 A5324 
Final Version 2.0  
  08/25/17  
 
 
1.3.5  To assess the association between serum and CSF biomarkers, neuropsychological performance , and DTG and MVC pharmacokinetics  (PK) 
throughout the course of the study . 
 
1.3.6  To assess  whether the addition of DTG  alone (Arm B) or DTG and MVC  (Arm C)  
is associated with maintenance of plasma HIV -1 RNA <50 copies/mL . 
 1.3.7  To assess changes in blood CD4+/CD8+ counts after intensification with DTG  
and MVC  (Arm C), DTG alone (Arm B) or placebos  (Arm A). 
 
1.3.8  To determine associations between peripheral bl ood immunologic  markers 
(s100β , soluble CD14) and changes in neurocognitive function at week 48 . 
 1.3.9  To determine the relationship between changes in CCR5 ligand levels (MIP -1b) 
and inflammatory marker changes  in both peripheral blood and CSF.   
 
1.3.10  To determine the effect of DTG intensification on residual viremia, cellular HIV -1 
RNA expression, total cellular HIV -1 DNA , and 2  long terminal repeat sequences 
(LTR) DNA, and to determine whether these virologic changes are  associated 
with week 48  neurocognitive function.  
  
2.0 INTRODUCTION  
 
2.1 Background/Rationale  
 
Despite effective suppression of plasma HIV- 1 RNA below levels of detection with highly 
active antiretroviral therapy (HAART), HIV -infected persons often have cognitive 
dysfunction (HIV -associated neurocognitive disorder, or HAND) , which includes 
asymptomatic neurocognitive impairment  (ANI) , mild neurocognitive disorder  (MND)  and 
HIV-associated dementia (HAD).  For example, in the ACTG Longitudinal Linked 
Randomized Trials (ALLRT) study , 458 (39%) of 1160 individuals receiving HAART had 
mild and 304 (26%) had mild- to-moderate neurocognitive impairment [ 1]. Similarly, in the 
CNS HIV Anti- Retroviral Therapy Effects Research ( CHARTER) study, 40% to 52% of 
the 1555 participants  were neuropsychologically impaired, including 42% 
neurocognitiv e impairment in those without other significant causes for impairment and 
who had undetectable plasma viral load [ 2]. The CHARTER study also documented the 
association between immune system functioning and neurocognitive impairment, with lower CD4+ lymphocyte nadirs predicting increased neurocognitive impairment. A study 
by Simioni et al . [3] found in participants who had undetectable plasma HIV -1 RNA 
(<50 copies/mL) on HAART and no cognitive complaints, 60% had ANI, 4% had MND, 
and none had HAD. Among those with cognitive complaints, 24% had ANI, 52% had 
MND and 8% had HAND.  
 International studies have provided estimates of neurocognitive impairment and examined the effects of ART on neurological and neurocognitive functioning in 
HIV. Two prior relevant AC TG studies, the i nternational neurological study (A5199, 
17 A5324 
Final Version 2.0  
  08/25/17  
 
“International Neurological Study: A Stand Alone Study for Participants of 
A5175”) and the i nternational neurocognitive normative s tudy (A5271, “Collection 
of Comparison Neurocognitive Data in Resour ce-Limited Settings”) found 
substantial prevalence of neurocognitive impairment at baseline in HIV+ ART-naïve participants in diverse resource- limited settings (RLS).  With ART, there were 
significant overall reductions in neurocognitive impairment over tim e [4, 5, 6, 7]. 
 These and other studies demonstrate that neurocognitive impairment is common among 
HIV-1-infected persons, despite effective ART. There have been several past clinical 
trials in HAND of potential promising agents, including selegeline, nimodipine, and 
minocycline, all unsuccessful  [8, 9, 10]. There are no current guidelines for the treatment 
of HAND.  
Cognitive impairment of treated individuals may be due to several, non- mutually  
exclusive factors including irreversible injury that occurred prior to ART, persistent 
production of HIV- 1 RNA in the central nervous system (CNS) compartment  [11], 
toxicities of ART  [12, 13], or persistent CNS inflammation  [14]. In support of the latter 
hypothesis, several studies have demonstrated elevated markers of immune activation 
in the CSF of participants with undetectable plasma HIV -1 RNA on ART  [15]. Thus, 
control of plasma viral replication to <50 copies/mL may not be sufficient to prevent or 
reverse cognitive impairment. Controversy remains as to whether HAART that better 
penetrates into the CNS is important in treating or preventing HAND. Such treatment 
may reduce residual low- level viral replication within the CNS, and potentially reduce 
consequent pathologic CNS immune activation. 
 
A CNS Penet ration Effectiveness (CPE) method  ranks  available antiretroviral (ARV)  
penetration into the CNS based on several factors  [16]. The 2010 revision of the CPE 
scale ranks CNS penetration on a 4- point scale , where 1 is the lowest and 4 is the 
highest relative CNS penetrance; for example, tenofovir (TDF) is ranked 1 and 
emtricita bine (FTC) is ranked 3 (Table 1). MVC is ranked at 3. Initial data on CSF 
penetration of DTG are promising. The median DTG concentrations in CSF were 18 ng/mL (range, 4 -23 ng/mL) at week 2 and 13 ng/mL (4 -18 ng/mL) at week 16. Ratios 
of DTG CSF to total plasma concentration were similar to the unbound fraction of DTG in plasma [17]. Higher CNS penetration of  ART is associated with lower CSF HIV -
1 RNA in cross -sectional analyses  [18, 19] and results in greater decreases in CSF HIV -
1 RNA in longitudinal analyses  [13, 20], but has not conclusively been shown to improve 
neuropsychological performance in cognitively impaired individuals. Although the 
existing observational data are provocative, a change in clinical practice and treatment 
guidelines will require randomized controlled trials that carefully evaluate the risk as well as potential benefits of targeting or augmenting the CPE of ART  for indivuduals with 
mild c ognitive impairment.  
18 A5324 
Final Version 2.0  
  08/25/17  
 
Table 1. CNS Penetration- Effectiveness Ranks  [19] 
CLASS  4 3 2 1 
NRTIs  
(nucleoside reverse 
transcriptase inhibitors ) Zidovudine (ZDV)  Abacavir (ABC)  
Emtricitabine 
(FTC) Didanosine (ddI ) 
Lamivudine (3TC)  
Stavudine (d4T)  Tenofovir (TDF) 
Zalcitabine (ddC)  
NNRTIs   
(nonnucleoside reverse 
transcriptase inhibitors)  Nevirapine (NVP)  Delavirdine (DLV)  
Efavirenz (EFV)  Etravirine (ETR)   
PIs  
(protease inhibitors)  Indinavir/  Ritonavir 
(IDV/r)  Darunavir/  
Ritonavir (DRV/r) 
Fosamprenavir/  
Ritonavir (FPV/r) 
Indinavir (IDV)  
Lopinavir/  
Ritonavir (LPV/r)  Atazanavir (ATV)  
Atazanavir/  
Ritonavir (ATV/r) 
Fosamprenavir 
(FPV)  Nelfinavir (NFV)  
Ritonavir (RTV)  
Saquinavir (SQV)  
Saquinavir/  
Ritonavir (SQV/r) 
Tipra navir/  
Ritonavir (TPV/r) 
Entry Inhibitors   Maraviroc (MVC)   Enfuvirtide (ENF)  
Integrase Inhibitors  Dolutegravir  
(DTG)  Raltegravir (RAL)    
 
We propose to assess the efficacy of adding the  C-C chemokine receptor type 5 
(CCR5 ) antagonist MVC  (Class 3 CPE) and the integrase inhibitor DTG  (Class 4 CPE) 
to the current ART of persons with undetectable (<50 copies/mL) plasma HIV -1 RNA 
who have mild- to-moderate neurocognitive impairment with a primary outcome of 
improvement in neurocognitive performance. We have chosen a three -arm design 
comparing: ( Arm A ) placebos for MVC and DTG , (Arm B) DTG  active drug and MVC  
placebo, and ( Arm C) MVC and DTG  active drugs.  This design will allow us to determine  
the neurocognitive effects of  each drug combination (all pai rwise comparisons, a rm B 
versus arm A, a rm C versus a rm A, and a rm C versus a rm B ). MVC  was chosen for this 
study because: 1) its concentrations in CSF consistently exceed the 50% inhibitory concentration for CCR5 -using (R5) strains of HIV  [21, 22]; 2) the primary  target cells for 
HIV in the nervous system, microglia, express predominantly CCR5 but not C-X- C 
chemokine receptor type 4 ( CXCR4 ); 3) inhibition of CCR5 may decrease migration of 
lymphocytes into the CNS thereby diminishing inflammation in the CNS compart ment  
[23]; and 4) it is well tolerated. DTG  was chosen for this study because: 1) its 
concentrations in CSF also consistently exceed the 50% inhibitory concentration for wild-
type HIV; 2) it is a member of a novel drug class that has reliable antiviral acti vity in 
integrase inhibitor -naïve individuals; and 3) it is well tolerated. Since eligible 
participants  will have plasma HIV-1 RNA  levels <50 copies/mL, performance of tropism 
and resistance assays will not be possible at the time of study screening; however, this 
testing can be applied to virological failures during the study , should the need arise.  The 
potential novel properties of MVC  on the CNS justify using it in this setting, along with 
the fact that all intensified participants will receive DTG,  which is an active drug. While 
it is possible to assess proviral DNA tropism, this will not be done prospectively since the clinical relevance of the findings is unknown. However, depending upon the results of 
this study, consideration can be given to performing these assays retrospectively on stored peripheral blood mononuclear cells . In designing the intervention, DTG was 
19 A5324 
Final Version 2.0  
  08/25/17  
 
chosen as the single additional drug (Arm B) because in addition to having the favorable 
properties outlined above, it is expected to be an  active agent in all enrolled 
participants , which is limited to those who are integrase inhibitor naïve. Because MVC 
does not have activity against CXCR4- using viruses , and there is one study suggesting 
that MVC may promote rather than suppress peripheral immune activation, we will not 
evaluate MVC as a single additional agent. 
 The study design is also well suited to assess the effects of intensification with an 
integrase inhibitor  alone or in combination with an entry inhibitor  on residual virem ia, 
cellular HIV -1 RNA expression and 2 -LTR circle formation , using specimens through 
week 12,  as well as the relationship between these indicators of low -level HIV 
replication  and neurocognitive function at 48 weeks . The design would allow us to 
confirm (or refute)  the findings of Hatano et al ., who performed a randomized, 
double- blind, placebo- controlled trial of raltegravir intensification  [24]. The trial 
found that 2 weeks of raltegravir increased the number of 2- LTR circles by more 
than five -fold, compared with placebo, indicating that low -level HIV replication had 
been present prior to raltegravir intensification and supporting that intensification 
with an integrase inhibitor may better suppress it.  
 
Rationale for 96- Week Follow -up 
Including an assessment  at 96 weeks in A5324 i s important for several reasons:  
 First, if a neurocognitive benefit is observed, understanding the durability of the 
improvement and potential long- term toxicities will be important. For this reason, many 
clinical trials follow participants  until 96 weeks and sometimes longer to assess both 
long- term efficacy and safety.  
 
Second, compared with ARV -induced changes in HIV -1 RNA levels and CD4+ T- cell 
counts, the dynamics of neurocognitive improvement in people with HAND are much 
slower. For in stance, Cysique et al . [20] showed that neurocognitive functioning 
continues to improve every 12 weeks after initiating ART . After 48 week s of ART, the 
modeled regression line of neurocognitive change still had an upward slope, indicating 
that functioning was continuing to improve. Importantly, participants in this analysis had 
detectable HIV -1 RNA levels in blood before changing ART.  This long- term improvement 
in neurocognitive scores was also seen in A5199,  and persisted to 96 weeks of follow-
up. Participants  in A5324 will have undetectable HIV -1 RNA levels in blood prior to 
augmenting their ART and may have even slower improvement in neurocognitive functioning.  
 Third, maximum ARV effectiveness in the CNS does not occur until approximately 18 
months of treatment. Specifically, in  the NIH -funded CHARTER cohort, the proportion 
of treated participants who had detectable HIV- 1 RNA levels in CSF declined  over this 
time frame . In this analysis, recursive partitioning identified informative threshold values 
in the duration of the current ART: <7.2 months: 19.6% detectable HIV -1 RNA in CSF; 
7.2 to 18.8 months: 16.6%; 18.8 to 57.4 months: 8.1% (S. Letendre, personal communication, 2014). While multiple factors may explain this finding, evaluating participants  for longer than 18 months is needed  to assess the effects of maximum viral 
suppression.  
20 A5324 
Final Version 2.0  
  08/25/17  
 
 
MVC (Selzentry ) 
MVC, in combination with other potent ARV drugs, is approved for suppressing R5 HIV -1 
in treatment -naïve and experienced individuals . In the MERIT trial, MVC 300 mg once a 
day (QD) or 300 mg twice a day ( BID) was compared to efavirenz ( EFV) 600 mg QD, 
each in combination with Lamivudine ( 3TC)/zidovudine ( ZDV) (300/150 mg BID, 
Combivir ). The MVC 600 mg QD arm failed to meet predefined criteria for non- inferiority 
to EFV and was prematurely discontinued at week 16. At week 48, MVC 300 mg BID 
failed to show non- inferiority to EFV for the primary endpoint of plasma HIV -1 RNA <50 
copies/mL (65.3% vs. 69.3%), although there was no difference in the proportion who achieved plasma HIV- 1 RNA <400 copies/mL  [25]. In the MERIT- ES study  [26], data 
were reanalyzed after Enhanced Sensitivity Tropism Assay (TrofileES) was used to 
discriminate participants with exclusive R5 HIV -1 from those with X4 or dual/mixed 
strains with improved precision (sensitivity of approximately 0.3%) compared to the 
earlier Trofile assay. This re -analysis, using intent -to-treat (ITT) , demonstrated similar 
suppression of R5  HIV (68% plasma HIV RNA <50 copies/mL) with EFV or MVC. There 
were fewer instances of rash, neurologic symptoms, and lipid changes in the MVC 
group. These results were confirmed at week 96 (59% vs. 62% suppressed), although, 
in general, more participants discontinued EFV due to AEs while more discontinued 
MVC due to virologic failure ( VF) [27]. There was a greater mean increase in CD4+ T -
cell count with MVC compared to EFV. Early failure of MVC appears due to outgrowth of 
pre-existing X4 or dual/mixed variants under selective drug pressure and later failure 
due to resistance of R5 variants.  
 In MOTIVATE,  treatment -experienced individuals witho ut detectable CXCR4- using 
virus were randomized to optimized background ARV regimen with or without QD or BID dosing of MVC. In this case,  approxima tely 50% of participants  in the QD arm and 63% 
of participants  in the BID arm had evidence of non- R5 strains at the time of failure with 
no apparent immunologic consequences  [28, 29]. On the other hand, MVC resistance 
occurred in approximately one- third of p articipants who failed with R5 -tropic HIV  [29, 
30]. The mechanisms of MVC resistance are not completely understood, but selection of 
mutations in the viral envelope gp120 molecule may allow HIV -1 to regain activ ity 
despite CCR5 inhibition with MVC  [31].  
 
DTG ( Tivicay ) 
DTG is an integrase inhibitor approved for use in combination with other antiretrovirals in 
treatment -naïve and experienced HIV-1-infected adults and children aged 12 years and 
older and weighing at  least 40 kg. The recommended dose of DTG  in treatment naïve or 
treatment -experienced, integrase -naïve individuals is 50 mg QD , but when 
coadministered with potent UGT1A/CYP3A inducers such as EFV, fosamprenavir/ ritonavir (FPV/r) , tipranavir/ ritonavir ( TPV/r), or rifampin  (RIF) , a dose 
adjustment of DTG  to 50 mg BID is needed in these individuals. The recommended 
dose of DTG in integrase -experienced individuals with certain integrase -associated 
resistance substitutions (L74I/M, E138A/D/K/T, G140A/S, Y143H/R, E157Q, 
G163E/K/Q/R/S, or G193E/R) or clinically suspected integrase resistance is 50 mg BID . 
Additionally, in these individuals, alternative combinations that do not include metabolic 
inducers should be considered when possible.   
 
21 A5324 
Final Version 2.0  
  08/25/17  
 
DTG  is metabolized by the UGT1A1 metabolic pathway with minor CYP3A4, UGT1A3, 
and UGT1A9 components. DTG  has a terminal half -life of approximately 14 hours and 
an apparent clearance (CL/F) of 1.0 L/h based on population PK analyses. Following 
oral administration of DTG , peak pl asma concentrations were observed 2 to 3 hours 
postdose. DTG  tablets may be taken with or without food.   
 
In vitro, DTG  did not inhibit or induce cytochrome P450 enzymes. DTG  is therefore not 
expected to affect the PK of drugs that are substrates of CYP450. DTG  should not be 
used with etravirine (ETR)  without coadministration of atazanavir/ritonavir  (ATZ/r) , 
darunavir/ritonavir  (DRV/r) , or lopinavir/ritonavir  (LPV/r, Kaletra) . Coadministration with 
nevirapine (NVP)  should be avoided because there are insuf ficient data to make dosing 
recommendations. Coadministration with metabolic inducers such as oxcarbazepine, 
phenytoin, phenobarbital, carbamazepine, and St. John’s w ort  should be avoided 
because there are insufficient data to make dosing recomme ndations.  DTG  should be 
taken 2 hours before or 6 hours after taking cation- containing antacids or laxatives, 
sucralfate, oral iron supplements, oral calcium supplements, or buffered medications.    
 
In vitro, DTG  inhibited the renal organic cation transporter, OCT2 (IC50 = 1.93 μM). In 
vivo, DTG  inhibits tubular secretion of creatinine by inhibiting OCT2. Thus, 
coadministration of DTG  with dofetilide is contraindicated due to the potential for 
increased dofetilide plasma concentrations and the risk for serious and/ or life -
threatening events. In addition, monitoring of glucose levels is recommended when starting or stopping DTG  and metformin together , as a dose adjustment may be needed 
for metformin.   
 
DTG is highly protein -bound (approximately 99%) based on in vitro data, and in healthy 
individuals , DTG has a mean unbound fraction of approximately 0.23%  [32].  
 
The efficacy of DTG in HIV -1-infected treatment naïve individuals  was based on 48 -
week data from two randomized, international, multicenter, double- blind, act ive-
controlled trials, SPRING 2 (ING113086) and SINGLE (ING114467). In SPRING 2, 822 participants  were randomized and received either DTG 50 mg QD  or raltegravir ( RAL) 
400 mg BID, both in combination with fixed -dose dual nucleoside reverse transcriptase 
inhibitor  (NRTI ) backbone (either abacavir[ ABC]/3TC  or TDF/FTC)  [33]. At 48 weeks, the 
proportion of participants with HIV -1 RNA <50 copies/mL was 88% in the DTG group 
compared with 85% in the RAL group (adjusted difference 2·5%; 95% confidence interval  (CI) –2·2 to 7·1). The median increase from baseline to w eek 48 in CD4+ cell 
count was 230 cells/mm
3 in both groups. The most common (≥10%) AEs (all grades) for 
DTG vs. RAL groups were nausea (14% vs. 13%), headache (12% vs 12%), 
nasopharyngitis (11% vs 12%), and diarrhea (11% in each group). Few participants  
had drug -related serious AEs (3 [<1%] vs. 5 [1%]), and few discontinued due to AEs (2%  
in each group). Rates of laboratory abnormalities were similar between treatment 
groups, and no clinically significant changes in the fasting lipid profile were noted in 
either group. Nonpathologic inhibition of the organic cation transporter, OCT2, in the 
proximal renal tubules  [34] resulted in small, non- progressive increases in serum 
creatinine early in treatment with DTG (weeks 2- 4) and then remained stable to week 48, 
consistent with previous findings  [35]. No participants on the DTG or the RAL arm 
discontinued ART due to renal AEs. No evidence of treatment -emergent resistance was  
22 A5324 
Final Version 2.0  
  08/25/17  
 
observed in participants  with VF on DTG,  whereas among RAL- treated participants , 
one had integrase treatment -emergent resistance and four had NRTI treatment -
emergent resistance.  
 
In SINGLE, 833 participants were randomized and received either DTG 50 mg QD  with 
fixed -dose ABC/3TC or fixed- dose TDF/FTC/EFV  [36]. At 48 weeks, the proportion of 
participants  with HIV-1 RNA <50 copies/mL was 88%  on DTG compared with 81% on 
TDF/FTC/EFV (adjusted difference 7.4%; 95% confidence interval 2.5% to 12.3%; 
p=0.003). The adjusted median increase from baseline in CD4+ cell count was 267 
cells/mm3 for DTG+ABC/3TC vs. 208 cells/mm3 for TDF/FTC/EFV at 48 weeks (adjusted 
difference 59%; 95% CI , 33% to 84%). The most common (≥10%) AEs for 
DTG+ABC/3TC vs. TDF/FTC/EFV groups were dizziness (7% vs. 32%), nausea (10% 
vs. 12%), abnormal dreams (6% vs. 15%), and insomnia (10% vs. 5%). The number of 
participants  who discontinued study due to AEs for DTG+ABC/3TC was 10 (2%) 
compared with 41 (10%) on TDF/FTC/EFV groups. Few participants had drug- related 
serious AEs (1 [<1%] vs. 8 [2%]). Renal AEs leading to discontinuation occurred in one participant  on DTG+ABC/3TC and two participants on TDF/FTC/EFV. At 48 weeks, 
small increases were noted in total, low density lipoprotein (LDL) and high density 
lipoprotein (HDL) cholesterol in both groups but total cholesterol/HDL ratio remained stable; comparable increases in triglycerides were observed in both groups. No evidence 
of treatment -emergent resistance was observed in participants with VF on DTG, 
whereas among TDF/FTC/EFV -treated participants, four had nonnucleoside reverse 
transcriptase inhibitor  (NNRTI ) treatment -emergent resistance and one had major NRTI 
treatment -emergent resistance.  
 
DTG in CSF  
The  distribution and antiviral activity of DTG in CSF has been studied in 13 treatment -
naïve participants on a stable regimen of DTG+ABC/3TC through 16 weeks  [17]. 
Median change from baseline to w eek 16 in CSF (N=11) and plasma (N=12) HIV -1 RNA 
were -3.42 log 10 and -3.04 log 10 copies/mL, respectively. Nine of eleven (82%) 
participants  had both plasma and CSF HIV -1 RNA <50 copies/mL and 10/11 (91%) 
participants  had CSF HIV-1 RNA <2 copies/mL. At 16 weeks, the median (range) DTG 
concentration in CSF was 13.2 (3.7- 18.3) ng/mL with CSF:plasma DTG concentr ation 
ratio of 0.41 (0.3 -2.04) . These data indicate that DTG therapeutic concentrations were 
achieved in CSF, with DTG CSF concentrations exceeding the in vitro 50% inhibitory concentration for wild- type viruses in peripheral blood mononuclear cells (0.2 ng/mL)  
[37] and decreases in CSF HIV -1 RNA levels were similar to decreases in plasma HIV -1 
RNA levels.  
 
Biomarkers  
The search for clinically relevant biomarkers for HAND is another important, and largely 
unmet, need of the field. Many biomarkers have been investigated but an extensive 
panel is beyond the scope of this project. Instead, the project will measure a concise panel of biomarkers and store fluid to enable more in- depth investigations in the future. 
 
• Peripheral blood  
As evaluations for this study will involve neuropsychological testing and classification of participants prior to and following randomization, we propos e to 
23 A5324 
Final Version 2.0  
  08/25/17  
 
additionally investigate the possible correlation between HAND diagnosis, 
neuropsychological test results,  and biomarkers of CNS injury . S100β is a 
calcium -binding protein produced by astrocytes that is elevated in the serum in 
the context of traumatic brain injury, brain ischemia and hemorrhage, active CNS lupus erythematosis, and Human T- lymphotropic virus Type 1 ( HTLV -1)-
associated tropical spastic paraparesis (but not asymptomatic HTLV -1 infection)  
[38, 39, 40, 41]. Glial activation with elevated CSF expression of S100β has 
been identified in individuals infected with HIV -1 [42], and higher CSF S100β is 
associated with neurocognitive impairment in people infected with HIV -1 [43, 44]. 
No studies have investigated the relationship between serum S100β and brain 
injury in HIV. We propose to use the opportunity afforded by the detailed 
neuropsychological characterization of enrolled participants  to assess whether 
S100β  might be a peripheral blood biomarker for HIV -associated CNS 
disease/HAND. In addition to S100β, we will measure the serum concentration of the soluble form of the receptor for bacterial lipopolysaccharide (LPS), CD14, 
based on the theory of microbial translocation- associated immune activation in 
HIV disease [ 45]. In vitro and animal model studies suggest that LPS may lead to 
neurological injury by augmenting trafficking of infected and activated monocytes 
across the blood- brain barrier  [46]. Human studies have also linked LPS and 
soluble CD14 to HAND  [47].  
 sCD163 is a soluble marker of monocyte/macrophage activation that has been 
associated with surrogate markers of cardiovascular disease [ 48] and 
neurocognitive dysfunction in treated HI V infection  [49]. D-dimer is a coagulation 
marker that is increased in inflammatory states including treated HIV infection and strongly predicts all -cause mortality in this setting [ 50]. MIP -1b is a natural 
CCR5 ligand, which has been shown to increase at least 2 -fold in plasma during 
MVC  intensification  [51] due to blockade of ligand- receptor complex 
internalization.  The extent of MIP -1b elevation during MVC  intensification is thus 
a reasonable surrogate marker for the degree to which MVC  is preventing natural 
signaling through CCR5 in vivo . 
 
• CSF 
In the subset of participants who agree to undergo an optional lumbar puncture 
(LP) for CSF collection, we will assess CSF concentrations of selected 
biomarkers. CSF concentrations of neopterin, monocyte chemoattractant protein-1 (MCP -1), and Interferon gamma- induced protein 10 (IP- 10) are increased in 
people infected with HIV- 1 and are indicators of macrophage activation, 
monocyte- derived macrophage chemotaxis , and lymphocyte chemotaxis  [14, 52, 
53, 54, 55, 56, 57, 58]. Neurofilament light chain (NFL) is a sensitive biomarker 
of axonal injury that can be assayed in CSF (and peripheral blood)  [59, 60, 61, 
62, 63]. 
 While these example biomarkers in plasma and CSF are of current inter est, there 
are often substantial changes over time with the development of new more sensitive and specific biomarkers. As research adds to the knowledgebase in this 
area, the team will implement and assess the most  scientifically rigorous and 
relevant biomarkers at study conclusion.  
24 A5324 
Final Version 2.0  
  08/25/17  
 
 
3.0 STUDY DESIGN  
 
This is a phase IV randomized, double- blinded, placebo- controlled clinical trial. 
Participants  will have at least mild HAND as defined by the Frascati criteria , plasma 
HIV-1 RNA <50 copies/mL within 90 days prio r to entry, no more than one plasma HIV- 1 
RNA ≥50 and <200 copies/mL in the 6 months  prior to entry  with a subsequent plasma 
HIV-1 RNA  <50 copies/mL, and on stable ART  for at least 6  months  prior to entry  with no 
plans to change treatment  except for the allowed changes defined in sections 4.1.2 
and 4.1.3. Participants will be randomized to one of three study arms to  add to their 
existing ART, placebo for MVC , and placebo for DTG  (Arm A) , DTG  active drug and 
placebo for MVC  (Arm B ), or MVC and DTG  active drugs  (Arm C) . Randomization will be 
stratified by CD4+ nadir (≤100 vs. >100 cells/mm3) and HAND severity (ANI vs. 
MND/ HAD).  
  
Participants  will be assessed at screening and then every 24 weeks for 96 weeks with a 
neurocognitive battery. The tests in the neurocognitive battery have been implemented 
successfully in multisite clinical trials, and extensive training materials within the ACTG 
exist.  Appropriate country- and site -specific n ormative data will be used for 
comparison , and the battery is designed to adhere to the recommendations of the 
Frascati consensus  [7, 64, 65]. These tests can have practice or learning effects upon 
repeated assessment; however,  alternate versions of the tests will be used at each 
visit to minimize this effect. In addition,  the placebo group (Arm A) will provide an 
estimate of practice effects and natural history in our analyses. A self -report assessment 
of functional ability, instrumental activities of daily living ( IADLs) , and psychological 
distress will be administered. In addition, an assessment of comorbidities and 
confounding factors based on the Frascati criteria  will be completed at screening then 
every 24 weeks for 96 weeks and used as a covariate.  Refer to the A5324 Manual of 
Operations ( MOP S) for details regarding the self -report assessments and the Frascati 
criteria. 
 
There will be clinical safety evaluation and monitoring at week  2, then c linical and 
laboratory safety evaluation and monitoring  at week 4, week  12, and every 24 week s 
beginning at week 24.  
 
Blood will be collected for hematology, chemistries, CD4+/CD8+ lymphocytes , and 
quantitative plasma HIV- 1 RNA, with plasma and serum collected and stored for single -
copy assay (SCA) and assessment of systemic immune and inflammation markers 
(s100β , soluble CD14 [sCD14], etc. ), respectively . PBMC will be cryopreserved at the 
indicated timepoints for future T- cell and monocyte phenotypic and functional studies as 
well as HIV reservoir measures (2- LTR circles and total cell -associated HIV -1 RNA and 
DNA).  
 A subset of consenting participants  will undergo LP at entry and 48 weeks.  
  
25 A5324 
Final Version 2.0  
  08/25/17  
 
4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS  
 
4.1 Inclusion Criteria  
 
4.1.1  HIV-1 infection, documented by : 
• A licensed rapid HIV test or HIV enzyme or chemiluminescenc e 
immunoassay (E/CIA) test kit at any time prior to study entry and 
confirmed by a licensed Western blot or a second antibody test by a 
method other than the initial rapid HIV and/or E/CIA, or by HIV -1 antigen 
or plasma HIV -1 RNA viral load  
NOTE: The term “licensed” refers to a United States Food and Drug Administration ( FDA)-approved kit , which is required for all IND 
studies, or for sites located in countries other than the United 
States, a kit that has been certified or licensed by an oversight body 
within that country and validated internally. Non- US sites are 
encouraged to use US FDA -approved methods for IND studies.  
WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial t est 
result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either 
another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different  test principle (eg, indirect versus 
competitive), or a Western blot or a plasma HIV- 1 RNA.  
OR 
• Documentation of HIV diagnosis  in the medical record by a 
healthcare provider  
 
4.1.2   On current  ART for at least 6  months  prior to study entry  with no interruption in 
treatment of ≥7 consecutive days . 
 Note: The following ART changes are allowed:  
• TDF to tenofovir alafenamide fumarate (TAF)/TAF- containing fixed -
dose combination regimens  
• RTV to cobicistat (COBI)/COBI -containing fixed- dose combination 
regimens   
 
4.1.3 No plans to change ART while on study.  
Note: The following planned ART changes are allowed:  
• TDF to TAF/TAF -containing fixed -dose combination regimens  
• RTV to COBI/COBI- containing fixed -dose combination regimens  
 
4.1.4  HIV-1 plasma RNA <50 copies/m L obtained within 90 days prior to study entry   
by any  FDA-approved assay at any  United States laboratory that has a Clinical 
Laboratory Improvement Amendments  (CLIA ) certification or its equivalent , or 
at any network -approved non- US laboratory that operates in accordance 
26 A5324 
Final Version 2.0  
  08/25/17  
 
with Good Clinical Laboratory Practices (GCLP) and participates in 
appropriate external quality assurance programs.  
 
4.1.5  No more than one HIV -1 plasma RNA ≥50 and <200 copies/mL (only one “blip”) 
in the past 6 months with a subsequent  HIV-1 plasma RNA <50 copies/mL.  
 NOTE: There should be no plasma HIV-1 RNA >200 copies/mL within the 6 
months prior to study entry.  
 4.1.6  HAND diagnosis ( ANI, MND , or HAD) within  60 days prior to study  entry .   
 
HAND is defined as at least mild impairment on neurocognitive testing (more 
than one standard deviation below appropriate normative data in two domains of functioning)  and no severely confounding factors . 
 
4.1.7 Screening laboratory values  obtained within 60 days prior to study entry  by any 
US laboratory that has a CLIA certification or its equivalent, or at any 
network- approved non- US laboratory that operates in accordance with 
GCLP and participates in appropriate external quality assurance programs: 
• Absolute neutrophil count (ANC) ≥500/mm
3 
• Hemoglobin ≥7 .5 g/dL  
• Platelet count ≥40,000/mm3 
• Creatinine ≤2 .0 x ULN 
• Aspartate transaminase ( AST) ≤5 x ULN   
• Alanine transaminase ( ALT) <3 x ULN  
• Alkaline  phosphatase ≤5 x ULN  
• Total bilirubin <1 .5 x ULN  
NOTE: If the potential participant  is taking an indinavir (IDV) - or 
atazanavir ( ATV)- containing regimen at the time of screening, total 
bilirubin ≤5 x ULN is acceptable. 
• Creatinine clearance (CrCl) ≥ 60 mL/min, either measured or estimated by 
Cockcroft- Gault equation   
NOTE: A calculator for estimating the CrCl can be found at www.fstrf.org/ACTG/ccc.html
 
 4.1.8 Females of reproductive potential (women who have not been post -menopausal 
for at  least 24 consecutive months, i .e., who have had menses within the 
preceding 24 mont hs, or women who have not undergone surgical sterilization, 
hysterectomy,  or bilateral salpingectomy , or bilateral oophorectomy or tubal 
ligation) must have a negative serum or urine pregnancy test by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a 
point of care (POC) / CLIA -waived test, or at any network -approved non- US 
laboratory or clinic that operates in accordance with GCLP and participates 
27 A5324 
Final Version 2.0  
  08/25/17  
 
in appropriate external quality assurance programs within 48 hours pri or to 
study  entry . 
 
4.1.9 Females of reproductive potential must agree not to participate in the conception 
process (ie, active attempt to become pregnant, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, must  use at least on e 
reliable form of contraception . Female participants must use contraceptives 
while receiving study treatment and for 6 weeks after stopping study treatment. 
 
Acceptable forms of contraception include:  
• Condoms (male or female) with or witho ut a spermicidal agent  
• Diaphragm or cervical cap with spermicide  
• Intrauterine device (IUD)  
• Hormonal contraceptive  
 
Females who are not of reproductive potential or whose male partner(s) has 
documented azoospermia are not required to use contraceptives. Any  statement 
of self -reported sterility or that of her partner’s must be entered in the source 
documents .  
NOTE:  Acceptable documentation of lack of reproductive potential is oral or 
written documentation from the participant . 
 
4.1.10 Men and women age ≥18 years who are able to complete the neuropsychological 
tests.  
 
4.1.11  Ability and willingness of participant  or a legal ly authorized representative (LAR; 
see section 4.3.1.1)  to provide informed consent . 
 4.1.12  Ability and willingness to take oral study medications.  
 
4.2 Exclusion Criteria  
 
4.2.1  Current or past medical condition(s) that, in the opinion of the investigator , 
prevents attribution of the cause of cognitive impairment to HIV. For example: 
4.2.1.1  Major depressive disorder with psychotic features  
4.2.1.2  Traumatic Brain I njury (TB I) with a clear impact on activities of daily 
living  
4.2.1.3  Developmetal delay , intellectual deficit,  and/or severe educational 
disability  resulting in some dependence for activities of daily living  
4.2.1.4  Ongoing substance use with significant impact on activ ities of daily 
living . Difficult or impossible to determine whether cognitive or 
functional decline is due to substance use or HIV, or both  
4.2.1.5  Evidence of intoxication or withdrawal during the screening evaluation  
28 A5324 
Final Version 2.0  
  08/25/17  
 
4.2.1.6  CNS infections or opportunistic conditions: B rain abscess  (bacterial, 
mycobacterial, fungal,  or Toxoplasma), meningitis with persistent 
neurologic impairment, primary CNS lymphoma , progressive multifocal 
leukoencephalopathy ( PML), or another  structural  brain lesion with 
neurological sequelae 
4.2.1.7  Other CN S conditions: Non- opportunistic primary or metastatic brain 
tumor s, uncontrolled seizure disorder, progressive multiple sclerosis, 
stroke with neurological sequelae, or dementia due to causes other 
than HIV (eg, Alzheimer ’s disease)  
4.2.1.8  Constitutional illness (e g, persistent unexplained fever, diarrhea, 
significant weight loss, disabling weakness)  within 30 days of screening  
4.2.1.9  Known untreated B12 deficiency or malnutrition (body mass index  [BMI]  
<18) at screening  
 
4.2.2  Evidence of current hepatitis C virus infection (HCV) (i e, HCV antibody  [Ab] 
positive within 90 days  prior to study entry  unless also shown to be plasma HCV 
RNA negative within the same time period). 
 
4.2.3  Unstable and advanced liver disease (as defined by the presence of at least one 
of the following: ascit es, encephalopathy, coagulopathy, hypoalbuminemia, 
esophageal or gastric varices, or persistent jaundice) . 
 
4.2.4  Prior or current use of any  CCR5  antagonist  (such as MVC and cenicriviroc 
[CVC]) and integrase inhibitor  (such as RAL, DTG, and elvitegravir  [EVG]) . 
 4.2.5  Current use of any medication, including antiretrovirals, prohibited in the study 
(refer to the A5324 protocol -specific web page [PSWP]  for the prohibited 
medications).  
 4.2.6  Breastfeeding.  
 4.2.7  Presence of an AIDS -defining opportunistic infection within 6 months  prior to 
 entry . 
Note: Refer to the A5324 MOPS for the list of AIDS -defining opportunistic 
infections.  
 4.2.8  Active syphilis or treatment for syphilis within 90 days prior  to study entry . 
NOTE: Active syphilis is defined as four -fold increase in serum rapid plasma 
reagin (RPR) or venereal disease research laboratory (VDRL) tests in an 
individual  with past syphilis, or newly reactive serum RPR or VDRL with a 
reactive confirmatory test ( enzyme immunoassays [EIA]  or chemiluminescent 
assay [CIA] , T. pallidum parti cle agglutination [TP -PA], or fluorescent 
treponem al antibody absorbed [FTA -ABS]) . 
29 A5324 
Final Version 2.0  
  08/25/17  
 
 
4.2.9  Known allergy/sensitivity or any hypersensitivity to components of study 
drugs or their formulation.  
 
4.3 Study Enrollment Procedures  
 
4.3.1  Prior to implementation of this protocol, and any subsequent full version amendments, each site must have the protocol and the protocol consent form(s) 
approved, as appropriate, by their local institutional review board (IRB)/ethics 
committee (EC) and any other applicable regulatory entity (RE). Upon receiving 
final approval, sites will submit all required protocol registration documents to the 
DAIDS Protocol Registration Office (DAIDS PRO) at the Regulatory Support  
Center (R SC). The DAIDS PRO will review the submitted protocol registr ation 
packet to ensure that all of the required documents have been received.  
 
Site-specific informed consent forms (ICFs) will be reviewed and approved by the 
DAIDS PRO, and sites will receive an Initial Registration Notification from the 
DAIDS PRO that indicates successful completion of the protocol registration 
process. A copy of the Initial Registration Notification should be retained in the 
site's regulatory files.  
 Upon receiving final IRB/EC and any other applicable RE approval(s) for an  
amendment, sites should implement the amendment immediately. Sites are 
required to submit an amendment registration packet to the DAIDS PRO at the RSC. The DAIDS PRO will review the submitted protocol registration packet to 
ensure that all required documents have been received. Site -specific ICF(s) will 
not be reviewed and approved by the DAIDS PRO and  sites will receive an 
Amendment Registration Notification when the DAIDS PRO receives a complete 
registration packet. A copy of the Amendment Registration Notification should be retained in the site's regulatory files. 
 
Sites that are registering for the first time with Version 2.0 should follow 
the protocol registration procedure for an initial registration.  
 
For additional information on the protocol registration process and specific 
documents required for initial and amendment registrations, refer to the current 
version of the DAIDS Protocol Registration Manual.   
 
Once a candidate for study entry has been identified, details will be carefully 
discussed with him or her . The participant  (or, when necessary, the  LAR [s ee 
section 4.3.1.1]) will be asked to read and sign the approved  protocol consent 
form.  
 
For participants  from whom a signed informed consent has been obtained, an 
ACTG Screening Checklist  must be entered through the Data Management 
Center (DMC) Subject Enrollment System.  
 
30 A5324 
Final Version 2.0  
  08/25/17  
 
4.3.1.1  Surrogate Consent by a Legally Authorized Representative  (LAR)  
 
A potential participant  who lacks the capacity to provide informed 
consent due to cognitive impairment may be considered if the 
participant  has a designated surrogate who can consent on his/her 
behalf.  The designated surrogate is a LAR  who has the ability to provide 
consent for the participant ’s participation in this research protocol as 
defined in the state and/or loc al laws.  
 
4.3.2  Protocol Activation  
 Prior to enrollment, sites must complete the Protocol Activation Checklist 
found on the ACTG Member website. This checklist must be approved prior 
to any screening of participants for enrollment.  
 
4.3.3  Randomization  
 
At the entry visit, participants will be randomized according to standard ACTG 
data management procedures.   
For participants  from whom informed consent has been obtained, but who are 
deemed ineligible or who do not enroll into the protocol, an ACTG Screeni ng 
Failure Results form  must be completed and keyed into the database .  
 
4.4 Coenrollment Guidelines  
 
• Sites  are encouraged to coenroll participants in A5128,  “Plan for Obtaining 
Informed  Consent  to Use S tored  Human  Biological  Materials  (HBM) for Currently  
Unspecified A nalyses .” Coenrollment in A5128 does not require permission from the 
A5324 protocol chairs.  
 
• Non-US sites are encouraged to co- enroll participants in A5243, “Plan for 
Obtaining Human Biological Samples at Non-U S Clinical Research Sites for 
Currently Unspecified Genetic Analyses.”  Co-enrollment in  A5243 does not 
require permission from the A5324 protocol chairs.  
 
• Sites that have been selected to participate in the “Imaging and Inflammatory 
Biom arkers in Anti -Retroviral Neuro Intensification  (SPIRIT) ” study are encouraged to 
coenroll  participants w ho are eligible. Coenrollment in the SPIRIT study  does not 
require approval of the A5324 protocol chairs.  
• For specific questions and approval for coenrollment in other studies, sites should first check  the PSWP or contact the protocol chairs via e- mail as described in the 
Study Management section. 
 
 
31 A5324 
Final Version 2.0  
  08/25/17  
 
5.0 STUDY TREATMENT  
 
Study treatment is defined as maraviroc (MVC) or placebo for maraviroc, and dolutegravir  (DTG)  or placebo for dolutegravir .  
 The study  treatment will be added to the current non-study- provided ART.  
 
5.1 Regimens, Administration, and Duration  
 
5.1.1  Regimens  
 Participants  will be randomized (1:1:1) to one of the three (3) following 
regimens:  
• ARM (A): Placebo for maraviroc  + Placebo for dolutegravir   
• ARM (B): DTG  + Placebo for maraviroc  
• ARM (C): MVC  + DTG  
 NOTE: Participants will receive the following regimen, based o n their existing 
ART therapy (see Tables A and B):  
• DTG  OR placebo for dolutegravir  
AND  
• MVC  OR placebo for maraviroc  
 
Table A.  
Background 
Regimen  ARM A  ARM B ARM C  
EFV + NRTI  Placebo for dolutegravir  
 
One (50 mg Placebo) 
tablet BID  DTG  
 
One (50 mg) tablet BID  DTG  
 
One (50 mg) tablet BID  
Placebo for maraviroc  
 
Two (300 mg Placebo) 
tablets BID  Placebo for maraviroc  
 
Two (300 mg P lacebo) 
tablets BID  MVC  
 
Two (300 mg) tablets BID  
 
RPV + NRTI  Placebo for dolutegravir  
 
One (50 mg Placebo) 
tablet QD  DTG  
 
One (50 mg) tablet QD  DTG  
 
One (50 mg) tablet QD  
Placebo for maraviroc  
 
One (300 mg Placebo) 
tablet BID  Placebo for maraviroc  
 
One (300 mg Placebo) 
tablet BID  MVC  
 
One (300 mg) tablet BID  
 
 
32 A5324 
Final Version 2.0  
  08/25/17  
 
Table B.  
Background 
Regimen  ARM A  ARM B ARM C  
PI/r + NRTIs  
 
OR 
 
PI/r + NNRTI 
+/- NRTI  Placebo for dolutegravir  
 
One (50 mg Placebo) 
tablet QD  DTG  
 
One (50 mg) tablet QD  DTG  
 
One (50 mg) tablet Q D 
Placebo for maraviroc  
 
One (150 mg Placebo) 
tablet BID  Placebo for maraviroc  
 
One (150 mg Placebo) 
tablet BID  MVC  
 
One (150 mg) tablet BID  
 
 
Any changes to the ART regimen, other than the allowed changes in 
section 7.6, should be discussed with the A5324 core team in advance 
(actg.corea5324@fstrf.org ). 
 
5.1.2  Administration and Dispensing 
 
All of the study products in the regimen should be taken with or without food. See 
section 10.2.1 for holding doses prior to the week 12 PK visit.   
 
5.1.2.1  MVC or placebo for maraviroc  will be administered orally as one 150 mg 
tablet BID OR two (300 mg) tablets  BID OR one 300 mg tablet BID 
depending upon background ARV regimen.  
 
5.1.2.2  DTG or placebo for dolutegravir  will be administered orally as one 50 
mg tablet BID OR  one 50 mg tablet QD depending upon background 
ARV regimen.  
 5.2 Study Product Formulation and Preparation 
 
5.2.1  MVC  150 mg tablets; 300 mg tablets. Store at room temperature 25°C (77°F); 
excursions pe rmitted to 15°C -30°C (59° -86°F) [see USP Controlled Room 
Temperature].  
 
5.2.2  DTG 50 mg tablets. Store at 25°C (77°F); excursions permitted to 15°C- 30°C 
(59°-86°F) [ see USP Controlled Room Temperature].   
 5.2.3  Placebo for maraviroc  150 mg tablets and Placebo for maraviroc  300 mg tablets. 
Store at 25°C (77°F); excursions permitted to 15° -30°C (59° -86°F) [see USP 
Controlled Room Temperature].  
 5.2.4  Placebo for dolutegravir  tablets. Store at 25°C (77°F); excursions permitted to 
15°-30°C (59° -86°F) [see USP Controlled Room Temperature].  
 
33 A5324 
Final Version 2.0  
  08/25/17  
 
5.3 Pharmacy: Product Supply, Distribution, and Accountability  
 
5.3.1  Study Product Acquisition/Distribution  
 
MVC and placebo for maraviroc  will be supplied by ViiV Healthcare Ltd.  
 
DTG and placebo for dolutegravir  will be supplied ViiV Healthcare Ltd.  
 
Study products  will be available through the NIAID Clinical Research Products 
Management Center (CRPMC). The site pharmacist can obtain the study products for this protocol by following the instructions in the manual Pharmacy 
Guidelin es and Instructions for DAIDS Clinical Trials Networks  in the section 
Study Product Management Responsibilities.  No other ARV therapy will be provided through the study.  
 
5.3.2  Study Product Accountability  
 The site pharmacist is required to maintain complete records of all study products received from the NIAID CRPMC and subsequently dispensed. At US  clinical 
research sites  (CRSs ), all unused study products must be returned to t he NIAID 
CRPMC (or as otherwise directed by the sponsor) after the study is completed or 
terminated. The procedures to be followed are provided in the Pharmacy 
Guidelines and Instructions for DAIDS Clinical Trials Networks.  At non -US 
CRSs, t he site pharmacist must follow the instructions in the Pharmacy 
Guidelines and Instructions for DAIDS Clinical Trials Networks  for the 
destruction of unused study products.  
 
5.4 Concomitant Medications  
 
Whenever a concomitant medication or study agent is initiated or a dose changed, investigators must review the concomitant medications’ and study  agents' most recent 
package inserts, Investigator’s Brochures, or updated information from DAIDS to obtain the most current information on drug interactions, contraindications, and precautions.  
 
Additional drug information may be found on the updated ACTG  Drug Interactions 
Database located at http://tprc.pharm.buffalo.edu/home/di_search/
.  
 
5.4.1  Prohibited Medications  
 
For a list of prohibited medications, refer to the PSWP.  
 
5.4.2  Precautionar y Medications  
 
For a list of precautionary medications, refer to the PSWP.  
34 A5324 
Final Version 2.0  
  08/25/17  
 
6.0 CLINICAL AND LABORATORY EVALUATIONS  
 
6.1 Schedule of Evaluations 
 
Evaluation  Screening  Pre-
Entry  Entry  Post-Entry Evaluations  
(Weeks)  Confirmation  
of  VF  Premature 
Study/Trea tment 
Discontinuation  
2 4 12 24 36 48 60 72 84 96 
Visit Windows     ± 1 wk  ± 2 wks  - 4 wks, + 8 wks    
Documentation of HIV -1 X               
Medical History  X  X             
Medication History  X  X             
Nadir CD4+    X             
Clinica l Assessment  X  X X X X X  X  X  X  X 
Neurological Exam    X      X       
Frascati HAND Rating Scale  X      X  X  X  X  X 
Neuropsychological Baseline 
Data  X               
Neurocognitive Batteries  X      X  X  X  X  X 
Questionnaires  X      X  X  X  X  X 
Adherence Assessment    X  X X X  X  X  X X X 
Study Medication 
Dispensing    X   X X X X X X X    
Hematology  X  X   X X  X  X  X   
Liver Function Tests  X  X  X X X  X  X  X   
Chemistry  X  X  X X X  X  X  X   
Urinalysis  X            X  X 
Pregnancy Tes ting X  X Whenever pregnancy is suspected   If pregnancy is 
suspected  
35 A5324 
Final Version 2.0  
  08/25/17  
 
Evaluation  Screening  Pre-
Entry  Entry  Post-Entry Evaluations  
(Weeks)  Confirmation  
of  VF  Premature 
Study/Trea tment 
Discontinuation  
2 4 12 24 36 48 60 72 84 96 
Visit Windows     ± 1 wk  ± 2 wks  - 4 wks, + 8 wks   
HCV Ab  X               
Syphilis Screening  X               
CD4+/CD8+    X   X X  X  X  X  X 
Plasma HIV -1 RNA  X  X   X X  X  X  X X X 
Stored Plasma   X X X X X X  X  X  X X X 
Stored Ser um   X    X  X    X  X 
Stored Viable PBMCs   X X X X X   X    X   
CSF supernatant and pellets 
(only in participants  who 
undergo LP)    X      X       
PK Studies       X X  X       
LP Safety Laboratory Tests  
(only in participants who 
will be undergoing LP)    X      X       
LP (Optional)    X      X       
Resistance Testing               X  
Tropism Testing               X  
 36 A5324 
Final Version 2.0  
  08/25/17  
 
 6.2 Timing of Evaluations  
 
6.2.1  Screening Evaluations   
 
Screening 
Screening evaluations to determine eligibility must be completed wit hin 60 days 
prior to study entry unless otherwise specified.  In addition to data being collected 
on participants who enroll into the study, demographic, clinical, and laboratory 
data on screening failures will be captured in a Screening Failure Results for m 
and entered into the ACTG database.  
 
Pre-Entry  
The screening and pre- entry vi sits can occur on the same day.  Sites have the 
option to complete the screening and pre- entry evaluations in stages (such as 
conducting the neurocognitive battery one day then the laboratory and clinical 
evaluations on another day) if it will be easier for the site and the participant . 
 Results of the screening and pre -entry evaluations must be received at least 24 
hours prior to entry.  
 
6.2.2  Entry Evaluations  
 
Entry evaluations must occur at least 24 hours after pre -entry unless otherwise 
specified. Participant  must begin treatment within 3 days  after randomization. 
 
6.2.3  Post-Entry Evaluations  
 
On-Treatment Evaluations   
Post-entry evaluations should occur following the visit  window s in the Schedule 
of Evaluations (SOE), section 6.1 . 
 
NOTE: The week 96 evaluations should be peformed as close to the week 96 
schedule as possible.  
 
Confirmation of  VF 
For participants  who have suspected VF, a confirmatory plasma HIV -1 RNA test 
and adherence assessment as per section 6.1 are to be performed within 30 
days after receipt by the site of the results of the initial HIV- 1 RNA sample 
indicating suspected VF. Participants who have their first plasma HIV- 1 RNA 
>200 copies/mL at their final st udy visit should be asked to return to the clinic for 
a confirmatory visit within 30 days of receipt of the result from their final visit.  
 
NOTE:  VF is defined as confirmed HIV -1 RNA levels >200 copies/mL after study 
entry.  
 
If the confirmation of VF visit coincides with a regularly scheduled visit, the 
evaluations should be combined.  
 37 A5324 
Final Version 2.0  
  08/25/17  
 
 Participants  who have confirmed VF  will discontinue the study  medications but 
will continue on study and followed through week 96. See sections 6.1 and 6.2.4 
for the procedures at premature treatment discontinuation.  
 
Samples drawn for resistance and tropism testing at the confirmation of VF visit 
should be stored.  The samples should be sent to the testing laboratory following 
the guidelines in sections 6.3.1 9 (Resistance Testing) and 6.3. 20 (Tropism 
Testing).  
 
6.2.4  Discontinuation Evaluations  
 
Evaluations for Randomized Participants  Who Do Not Start Study Treatment  
All case report forms (CRFs)  must be completed and keyed for the period up to 
and including the entry visit . No f urther follow- up is required.  Participants must 
be taken off study.  
 
Premature Treatment Discontinuation Evaluations   
Participants  who discontinue the study medications before the end of the study 
should have the premature treatment discontinuation evaluations done within 14 
days after stopping study  medications. Participants will be followed off study 
treatment/on study.  They  should be encouraged to continue to attend all study 
visits and receive study evaluations as per section 6.1, with the exception of the 
adherence questionnaire s, and optional lumbar puncture, through completion of 
the study.  
 
Premature Study Discontinuation Evaluations  
All participants  who prematurely discontinue participation in the study should 
have the premature study discontinuation evaluations done as per section 6.1. Participants  who prematurely discontinue participation in the study should report 
to the clinic to have the premature  study  discontinuation evaluations performed 
as soon as possible.  
 
6.3 Instructions  for Evaluations 
 
All clinical and laboratory information required by this protocol is to be present in the source documents. Sites must refer to the Source Document Guidelines on the  DAIDS  
website for information about what must be included in the source document:  
https://www.niaid.nih.gov/sites/default/files/sourcedocappndx.pdf
. 
 All stated evaluations are to be recorded on the CRF and keyed into the database 
unless otherwise specified. This includes events that meet the International Conference on Harmonisation (ICH) definitions for a serious adverse event: 
• Results in death  
• Life-threatening  
• Requires inpatient hospitalization or prolongation of existing hospitalization  
 38 A5324 
Final Version 2.0  
  08/25/17  
 
 • Results in persistent  or significant disability/incapacity  
• Congenital anomaly/birth defect 
• Other important medical event (may not be immediately life- threatening or result in 
death or hospitalization) but may jeopardize the patient or may require intervention to 
prevent one o f the events listed above.  
 To grade diagnoses, signs and symptoms, and laboratory results, sites must refer to the 
DAIDS Table for Grading the Severity of Adult and Pediatric AEs (DAIDS AE Grading Table), Version 2.1, March 2017, which can be found on the DAIDS RSC Web site:  
http://rsc.tech- res.com/clinical -research -sites/safety- reporting/daids -grading-
tables .   
 6.3.1  Documentation of HIV -1 
 
Section 4.1. 1 specifies  assay requirements and medical notes for HIV -1 
documentation.  HIV-1 documentation is not recorded on the CRF.  
 
6.3.2  Medical History  
 
The medical history must include all diagnoses identified by the ACTG criteria for clinical events and other diagnoses . In addition to reporting all diagnoses within 
the past 30 days  prior to study entry, the following diagnoses should be reported 
regardless of when the diagnosis was made :  
• AIDS -defining conditions  
• Bone fractures (verbal history accepted)  
• Coronary  heart disease  
• Cancer (exclusive of basal/squamous cell skin cancer)  
• Diabetes  
• Tuberculosis  
• Chronic hepatitis C  
• Chronic hepatitis B  
• Any neurologic disease  
 
Any allergies to any medications and their formulations must also be 
documented.  
 
6.3.3 Medication H istory  
 
A medication history must be present, including start and stop dates  (except as 
otherwise indicated on the CRF) . If only estimated start and stop dates are 
 39 A5324 
Final Version 2.0  
  08/25/17  
 
 available, these are acceptable. The table below lists the medications that must 
be included in the history  and recorded on the CRFs .  
 
Medication Category  Complete History or Timeframe  
ART Complete  
Immune -based therapy  30 days prior to study entry  
Blinded study treatment  30 days prior to study entry  
HIV-1-related vaccines  30 days prior to st udy entry  
Prescription drugs for treatment of 
opportunistic infections  30 days prior to study entry  
Prescription drugs for prophylaxis 
of opportunistic infections  30 days prior to study entry  
Prescription drugs (other)  30 days prior to study entry  
Alternative therapies  30 days prior to study entry  
Dietary supplements  30 days prior to study entry  
 
6.3.4  Nadir CD4+  
 
The participant’s  prior nadir CD4+ cell count (absolute value and date) should 
be documented when possible with a copy of the nadir CD4+ cell count report  or 
participant report . If this documentation is not available or the participant is 
unable to recall , either the best available information should be used or 
recorded as missing data in the CRF.  
 
6.3.5  Clinical Assessments  
 
Complete Physic al Exam  
A complete physical examination at screening is  to include at a minimum an 
examination of the skin, head, mouth, and neck; auscultation of the chest; cardiac exam; abdominal exam; and examination of the lower extremities for 
edema . The complete physical exam will also include height, weight, signs and 
symptoms, diagnoses, and vital signs (temperature, pulse, and blood pressure).  
 
Targeted Physical Exam  
After screening, a targeted physical examination, including height  (at entry and 
week 12 only) , weight, and vital signs (temperature, pulse, and blood pressure) 
should be per section 6.1,  along with additional assessments based upon 
previously identified findings, diagnoses , or new signs or symptoms since the last 
visit. 
 
Height  
Height in centimeters (cm) will be recorded on the CRF at the  entry visit only.  
 
 40 A5324 
Final Version 2.0  
  08/25/17  
 
 Weight  
Weight in kilograms  (kg) will be measured and recorded in the CRF at entry  and 
weeks 12, 24, and 48.  
 
Signs and Symptoms  
At entry, record on the CRFs all signs/symptoms occurring within 30 days prior to 
entry.  
 
After entry, all Gr ade ≥3 signs/symptoms, any signs/symptoms regardless of 
grade that lead to a change in treatment, that meet EAE, SAE, or ICH guidelines, or are defined by the protocol as reportable events that require detailed event 
reporting.  
 
Diagnoses  
At screening, rec ord diagnoses  in the medical history per section 6.3.2 . At study 
entry  and thereafter , record all new diagnoses since the last study visit  identified 
in the appropriate diagnoses appendix specified in the CRF. 
 
Concomitant Medications  
All current prescription medications (with start and stop dates) are to be recorded 
on the CRF. Current non -prescription medications are recorded in the source 
documents only. Alternative and traditional medications are reported as Yes/No on the CRF and keyed into the database. 
 Post -entry, new and discontinued prescription concomitant medications 
must be recorded on the CRFs.  
 
Study Treatment  Modifications  
At entry and weeks 4 to 96, r ecord  all study medication modifications, including 
initial doses , participant -initiated and/or protocol -mandated  modifications , and 
inadvertent and deliberate interruptions of ≥3 days . Record any permanent 
discontinuation of treatment. 
 
6.3.6  Neurological Exam  
 
The neurological exam will be performed only in participants  who consent to 
undergo the lumbar puncture procedure for collection of CSF. The exam  will be 
performed as scheduled in section 6.1. Refer to the A5324 MOPS  and the PSWP 
for specific details.  
 
6.3.7 Neuropsychological Baseline Demographic Data 
  
At screening, baseline demographic data, including age, educational level , and 
primary language will be collected.   
 
 41 A5324 
Final Version 2.0  
  08/25/17  
 
 6.3.8  Neurocognitive Batteries  
 
Neurocognitive testing will be performed as scheduled per section 6.1. This 
testing will take about an hour to c omplete. Refer to section 3.0 (Study Design), 
the A5324 MOP S, and the PSWP for additional information.  
 
Frascati HAND Rating 
Eligibility of the participant for the study will be based on the Frascati criteria  
for neurocognitive impairment.  An assessment of relevant confounding 
factors based on medical history and participant report are recorded on the 
CRF, and are a necessary part of the HAND diagnostic criteria.  Refer to the 
A5324 MOP S for description and instructions  for HAND diagnoses based on the 
Frascati criteria, which is determined by the A5324 Protocol Chair . 
 
Refer to the A5324 MOPS for the Frascati  HAND ratin g procedure for the 
post -entry visits.  
 
A5324 Neurocognitive Battery  
Based on the A5324 Neurocognitive battery administered at screening, participant impairment will be determined according to the Frascati criteria  for 
HAND diagnoses . The tests will be adm inistered based on CRS location as 
described below.   
 Neurocognitive Test Battery for CRS s in the United States:  
• Attention/Working Memory (Symbol Search , Trail Making A ) 
• Speed of Information Processing (Stroop Word, Stroop Color, Digit Symbol)  
• Executive Function (Trail Making B, Stroop Color/Word, Letter and Category Fluency)  
• Verbal Learning (Hopkins Verbal Learning Test Revised [HVLT -R]) 
• Verbal Memory (Delayed Recall – HVLT -R) 
• Fine Motor Skills/Complex Perceptual (Grooved Pegboard Bilateral) 
• Language/Premorbid Skills ( Wide Range Achievement Test 4 [ WRAT -
4] Reading OR Word Accentuation Test [ WAT ] for participants with 
Spanish as their primary language ) 
 
  Neurocognitive Test Battery for CRSs outside the United States:  
• Attention/Working Memory (Color Trails 1) 
• Speed of Information Processing (Digit Symbol)  
• Executive Function (Color Trails 2, Category Fluency)  
• Verbal Learning (HVLT -R) 
 42 A5324 
Final Version 2.0  
  08/25/17  
 
 • Verbal Memory (Delayed Recall – HVLT -R) 
• Fine Motor Skills/Complex Perceptual (Grooved Pegboard Bilateral , 
Fingertapping Bilatera l); Gross Motor (Timed Gait)  
• International HIV Dementia Scale (IHDS)  
 
6.3.9  Questionnaires  
 
Activities of daily living (ADLs) , psychological distress, and substance 
abuse will be assessed using self -report  questionnaires as scheduled in 
section 6.1. The following questionnaires will be administered:  
• Revised Lawton and Brody Activities of Daily Living Scale  
• Beck Depression Inventory II (BDI-II) (CRSs in the US only)  
• Patient Health Questionnaire (PHQ) -9 (CRSs outside the US only)  
• ACTG  Substance Abuse questionnaire  
 
Refer to the A5324 MOP S and PSWP for the specific information and 
instructions for completing the questionnaires . 
 
6.3.10 Adherence  Assessment  
 
Adherence to all study- provided and background ART medications will be 
assessed by self -report and completed as scheduled in section 6.1.  
 Sites will provide adherence reinforcement, according to standard practice, 
throughout the study. P articipants  with poor adherence (ie, less than 95%) 
will be provided counseling by the site.  
 6.3.11  Study Medication Disp ensing  
 
At study entry and thereafter, study medications will be dispensed every 12 
weeks. At weeks 36, 60, and 84, participants will return for study 
medication dispensing only. No other study evaluations will be performed.  
 
6.3.12 Laboratory Evaluations  
 
Record all protocol -required laboratory values, regardless of grade, obtained at 
screening and entry on the CRFs.  
 After entry, record:  
• all creatinine and liver function test (LFT) values,  
AND  
• Grade ≥3 for all other laboratory values. 
 43 A5324 
Final Version 2.0  
  08/25/17  
 
  
All laboratory values that lead to a change in study treatment, regardless of 
grade, must be recorded.  
 
Hematology  
Hemoglobin, hematocrit, white blood cell count (WBC), with differential including 
Absolute Neutrophil Count (ANC), and platelet count.  
 
Liver Function Tests ( LFTs)  
Total bilirubin, AST, ALT, alkaline phosphatase . 
 
Blood Chemistries  
Electrolytes (Na+, K+, Cl- , HCO 3/CO 2), glucose, creatinine, phosphate , and blood 
urea nitrogen.   
 
Urinalysis  
Dipstick urinalysis with microscopic examination if dipstick urinalysis is abnormal 
or when thought necessary by the investigator. Results will be recorded on the 
CRFs.  
 
Pregnancy Test  
For women with reproductive potential: serum  or urine β-HCG (urine test 
must have a sensitivity of ≤25 mIU/mL).  
 Negative pregnancy test must be obtained within 48 hours prior to study entry  for 
females of reproductive potential as defined in section 4.1.8 . After entry, perform 
a pregnancy test when pregnancy is suspected. Refer to section 7.3 for 
pregnancy and pregnancy outcome reporting require ments.   
 
Serologies  
HCV Ab must be performed at the screening visit in participants without an HCV 
Ab test result  within 90 days prior to study entry . 
 
Syphilis  
Screening for active syphilis will be done using nontreponemal test s (RPR or 
VDRL)  with reflex confirmation with treponemal test. If screening with a 
treponemal test (EIA, CIA, TP-PA, or FTA -ABS), a nontreponemal test must also 
be performed if the treponemal test is reactive.  
 
6.3.13 Immunologic Studies  
 
CD4+/CD8 + 
During the study, CD4+/CD8+ assays must be performed as indicated in section 6.1. For entry and post -entry evaluations, all laboratories must possess a 
CLIA certification or equivalent and must be  certified for protocol testing by the 
DAIDS Immunology Quality Assurance (IQA) Program.  
 
 44 A5324 
Final Version 2.0  
  08/25/17  
 
 The same assay must be used across all study visits. Due to diurnal variations in 
CD4+/CD8+ counts, determinations for individual participants should be 
obtained consistently in either the morning or the afternoon throughout the study, 
if possible.  
 NOTE: If th e lab is using dual platform technology to obtain the results, each time 
a measurement is obtained, the local lab must perform a WBC and differential 
from the sample collected at the same time.  
 
6.3.14  Virologic Studies  
 
Plasma HIV -1 RNA  
Screening HIV- 1 RNA must be performed within 90 days prior to study entry by a 
laboratory that possesses a CLIA certification or equivalent  using any FDA-
approved assay . Eligibility will be determined bas ed on the screening value.  
 HIV-1 RNA  on study  will be performed as scheduled in section 6.1 . The samples 
will be processed and shipped to the designated testing laboratory  associated 
with each non- US CTU/CRS or to Quest Diagnostics for each US CTU/CRS; 
plasma HIV -1 RNA will be performed in real -time using the current approved 
assay selected by the ACTG.  See the A5324 laboratory processing chart (LPC) 
for directions.   
 
6.3.15 Stored Samples     
 
EDTA blood for plasma and PBMC will be collected at the visits indicated on the 
SOE, section 6.1. Samples will be batch -tested at the end of the study.  See the 
A5324 LPC for processing, storage , and shipping directions. 
 
Plasma  
Plasma will be collected and stored for single copy assay (SCA) .   
 
Plasma collected at the confirmation of VF visit will be stored for resistance and 
tropism testing if VF is confirmed  (see sections 6.3.1 9 and 6.3.20).  
 
Serum  
Serum will be collected and stored for assessment of  the correlation of  systemic 
immune and inflammation markers ( s100β , sCD14 , etc. ) and 
neuropsychological test performance. 
 
Viable Peripheral Blood Mononuclear Cells ( PBMCs )  
Viably cryopreserved PBMC s from whole blood collected at visits indicated on 
the SOE,  section 6.1 , will be stored for future T cell and monocyte phenotypic 
and functional studies,  HIV reservoir measures (2 -LTR circle s and total cell -
associated HIV-1 RNA and DNA)  and future studies . HIV reservoir measures will 
be performed on samples collected at  pre-entry, entry , and weeks 2, 4,  and 12.     
 
 45 A5324 
Final Version 2.0  
  08/25/17  
 
 CSF 
See section 6.3.1 8 for CSF, CSF Supernatant , and CSF Pellets storage.  
 
6.3.16 PK Studies  (refer to section 10 ; see the A5324 LPC for processing, storage,  and 
shipping directions ) 
 
At week 12, samples for MVC and DTG levels will be collected pre -dose  and at 2 
and 4 hours post -dose. At weeks 24 and 48, samples will be collected pre-dose.  
 
6.3.17  Lumbar Puncture Safety Laboratory Tests  
 
Participants  who agree to undergo an optional LP  will need to have platelets 
and PT/INR measured within 1 week prior to the LP  only if there is a known 
history of  abnormalities  of bleeding and coagulation , including at time of entry,  or 
if the investigator has any concerns that the participant  may have a heightened 
bleeding risk.  For these participants  that require LP safety laboratory tests to 
be performed, the following safety criteria must be met  prior to the  LP: 
Platelet count ≥100,000   cells/mm3 
INR ≤1.4 
 
6.3.18  Lumbar Puncture (optional)  
 
In participants  who agree to undergo an optional LP , CSF will be collected at 
entry and week 48. 
 
At week 48, the CSF sample will be collected either after the observed morning 
dose or  1 hour  after the trough (pre -dose) sampling.  
 
The LP will not be performed in participants with known pregnancy due to risks 
of increased discomfort or difficulty with the procedure with advanced pregnancy.  
 
CSF S torage  
CSF will be stored at w eek 48 to measure concentrations of MVC, DTG and 
selected biomarkers.  
 
CSF Supernatant and CSF Pellets  
The CSF supernatant will be stored at e ntry and week 48 for studies of soluble 
markers already noted in the protocol, as well as potential studies of additional soluble markers of immune activation, neural biomarkers, and intensive virologic 
assays (for example, single copy assay HIV RNA quantitation) in the future, as 
allowed by new collaborations and funding support.    
 
The CSF pellets will be stored for future potential studies , which may include 
assays such as CSF immune cellular phenotyping and quantitation and sequencing of CSF cell -associated HIV- 1 DNA and RNA.  
 
 46 A5324 
Final Version 2.0  
  08/25/17  
 
 6.3.19 Resistance Testing 
 Perform only in participants who prematurely discontinue  study medications 
due to confirmed VF . The test will be performed in the designated  laboratory. 
See the A5324 LPC for processing, storage, and shipping directions. 
 If the HIV -1 RNA obtained at the confirmation of VF  visit is ≥1,000 copies/mL, a 
sample should be submitted for  HIV-1 resistance  testing and protease and 
integrase genotype testing.  
 
6.3.20  Tropism Testing  
 
Perform only in participants who prematurely discontinue  study medications 
due to confirmed VF . The test will be performed in the designated  laboratory.  
See the A5324 LPC for processing, storage, and shipping directions.  
 
If the HIV -1 RNA obtained at the confirmation of VF visit is ≥1000 copies/mL , 
then a sample should be submitted for  HIV-1 coreceptor tropism with reflex to 
ultradeep sequencing. If the HIV -1 RNA is <1 000 copies/mL, then a sample 
should be submitted for HIV- 1 coreceptor tropism, proviral DNA .  
  
7.0 CLINICAL MANAG EMENT ISSUES 
 7.1 Toxicity  Management  
 
Only toxicities related to study medications provided through this study (MVC, DTG , 
placebo for MVC, placebo for DTG ) will be considered in the toxicity management 
section. The grading system is located in the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 2.1, 
March 2017.   
 
For toxicities potentially attributed to one or more of the study medications , one or both 
of the study medications (or the  matching placebo) may be held or permanently 
discontinued. 
 
Participants  who have switched to any non- study ARV medication should be 
monitored for toxicity for that medication per standard of care and the site investigator 
should assure that no dose adjustments are needed for the study medications.   Any 
changes to the participant ’s background ARV regimen must be discussed with the 
core team ( actg.coreA5324@fstrf.org
). 
 
7.1.1 Grade 1 or 2  
 
Participants  who develop a Grade 1 or 2 AE or toxicity may continue study 
medications without alteration of the dosage  at the discretion of the 
investigator . Participants experiencing Grade 1 or 2 AEs who choose to 
 47 A5324 
Final Version 2.0  
  08/25/17  
 
 discontinue all study medications should complete the prematu re treatment 
discontinuation evaluations. The site investigator should contact the core team 
(actg.coreA5324@fstrf.org ), and the participant  should be encouraged to 
complete follow -up protocol study evaluations.  
NOTE: If participants  discontinue study medications due to Grade 1 or 2 AEs, 
this should be noted on the premature treatment discontinuation CRF as t he 
reason for discontinuation. 
 
7.1.2 Grade 3  
 
If the investigator has evidence that the AE  was NOT caused by study 
medications, dosing may continue. Grade 3 AE or toxicity must be evaluated and 
managed by the site investigator according to the standard of care. 
Discontinuation of one or both study medications may be necessary. 
Consultation with the core team is encouraged. The core team 
(actg.corea5324@fstrf.org ) must be notified by e -mail regarding toxicities that 
result in a change in regimen.  If study medication(s) are suspended the 
participant  should be reevaluated weekly until the AE returns to ≤  Grade 2 or 
baseline, at which time the study medications may be reintroduced, at the 
discretion of the site investigator or according to standard practice.  
 
If the same Grade 3 AE, excluding those AEs noted in the following sections, recurs within 4 weeks of restarting treatment, the suspected study medication 
must be permanently discontinued. However, if the same Grade 3 AE recurs after 4 weeks, the management scheme outlined above may be repeated.  
 
Participants  experiencing Grade 3 AEs requiring permanent discontinuation of 
one or both of the study medications should be followed weekly until resolution of the AE and should be encouraged to complete the premature treatment 
discontinuation evaluations and continue other study evaluations according to the 
protocol. The core team ( actg.corea5324@fstrf.org
) must be notified.  
 
7.1.3 Grade 4  
 
Participants  who develop a Grade 4 symptomatic AE or toxicity will have all 
study medications permanently discontinued except as indicated below . 
Participants  experiencing Grade 4 AEs requiring permanent discontinuation of 
all study medications should be followed weekly until resolution of the AE and 
encouraged to continue other study evaluations according to the protocol.  
Premature treatment discontinuation evaluations should be completed and 
recorded on the CRF and the core team ( actg.corea5324@fstrf.org ) must be 
notified. 
 
Asymptomatic Grade 4 abnormalities must be evaluated and managed by the 
site investigator according to the standard of care. Discontinuation of all study 
medications may be necessary. Consultation with the core team is encouraged. 
 48 A5324 
Final Version 2.0  
  08/25/17  
 
 The core team (actg.corea5324@fst rf.org ) must be notified by e -mail regarding 
toxicities that result in a change in regimen. 
 
7.1.4 AST or ALT Elevations  
 
All study medications may be continued for asymptomatic ≤ Grade 3 AST/ALT 
elevations, at the discretion of the site investigator. Careful assessments should 
be done to rule out the use of alcohol, non -study medication- related toxicity, or 
viral hepatitis (including viral hepatitis complicated by immune reconstitution inflammatory syndrome) as the cause of Grade 3 elevations.  
 For sympt omatic Grade 3 ( fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, or eosinophilia)  or any Grade 4 elevations in AST or 
ALT, all study medications should be held and the core team should be consulted 
(actg.corea5324@fstrf.org
). In addition, for  ALT ≥3 x ULN and bilirubin ≥1.5 x 
ULN (attempts should be made to fractionate the bilirubin), the study medications 
should be held and the core team consulted as this will likely result in permanent 
study medication  discontinuation.  
 
Participants  who develop symptomatic Grade 3 or any  Grade 4 AST or ALT 
elevation should be followed weekly until resolution to ≤ G rade 2. Participants 
will be fo llowed off study treatment, on study after study m edication  
discontinuation.  Refer to section 11.4.2 for the EAE reporting criteria for AST 
or ALT elevations.  
 
Participants  with Grade 3 or 4 AST or ALT elevation with fever, rash or 
eosinophilia should stop all study medications and not be re- challenged. T hese 
individuals should be followed weekly until resolution to ≤  Grade 2 elevation and 
should be followed off study treatment, on study. 
 
In consultation with the core team, careful assessments should be done to rule 
out the use of alcohol, non- study medication- related toxicity, or viral hepatitis 
(including viral hepatitis complicated by immune reconstitution inflammatory syndrome) as the cause of Grade 3 or 4 AST/ ALT elevations.  Evaluations to be 
considered (but are not required) include:  
• Viral hepatitis serology including: Hepatitis A IgM antibody; Hepatitis B Surface Antigen ( HBsAg ) and Hepatitis B Core Antibody (IgM); Hepatitis 
C RNA; Hepatitis E IgM antibody ; 
• Cytomegalovirus IgM antibody ; 
• Epstein- Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophil e antibody or monospot testing) ; 
• Syphilis screening; 
• Drugs of abuse screen including alcohol ; 
• Serum acetaminophen test (APAP adduct test) ; 
 49 A5324 
Final Version 2.0  
  08/25/17  
 
 • Serum creatine phosphokinase (CPK) and lactate dehydrogenase (LDH) ; 
• Anti-nuclear antibody, anti -smooth muscle  antibody, and Type 1 anti -liver 
kidney microsomal an tibodies ; 
• Liver im aging to evaluate liver disease . 
 
7.1.5 Calculated Creatinine Clearance (CrCl) Decline  
 
Non-study medications should be adjusted for decline in CrCl at the discretion of 
the primary pro vider per the standard of care.  CrCl should be calculated, using 
the Cockcroft -Gault E quation, at each post -entry visit when serum 
creatinine is measured. Refer to section 4.1.7 for the Cockcroft -Gault 
Equation calculator.  
 
MVC use is not allowed for CrCl <30 mL/min. MVC or placebo for MVC  should be 
discontinued in this setting and then restarted if CrCl increases to 30 mL/min or above.  
 
7.1.6 Postural Hypotension  
 
If a participant  develops postural hypotension of any grade, the investigator 
should contact the core team ( actg.corea5324@fstrf.org
).  
 7.1.7 Allergic Reaction   
 
Participants  may continue study medication for Grade 1 or 2 allergic reactions at 
the discretion of the site investigator. The participant  should be advised to 
contact the site investigator  immediately if there is any worsening of symptoms or 
if further systemic signs or symptoms develop. Antihistamines, topical 
corticosteroids, or antipruritic agents may be prescribed.  
  
Participants  with ≥ Grade 3 allergic reactions that are considered to be possibly 
or probably related to the study medications should permanently discontinue the 
putative study medication or medications and continue to be followed off study 
treatment , on study. The participant  should not be re -challenged. The 
participant  should be treated as clinically appropriate and followed until 
resolution of the AE.    
 
Allergic reactions that include but are not limited to severe rash or any rash with 
fever, general malaise, fatigue, muscle or joint aches, oral lesions, conjunctivitis, 
facial edema or eosinophilia should result in all study medications being stopped and the participant  should not be re -challenged. The participant  should be 
followed off study treatment, on study.  
 
 50 A5324 
Final Version 2.0  
  08/25/17  
 
 7.1.8 R ash  
 
Mild to moderate rash is an expected adverse reaction for DTG -containing ART. 
Episodes generally occur within the first 10  weeks of treatment, rarely require 
interruptions or discontinuations of therapy and tend to resolve within two to three 
weeks.  A single case of hypersensitivity with DTG involved a profuse, purpuric 
and coalescing leukocytoclastic vasculitis as well as clinically significant liver 
chemistry  elevations.  Other than this case, no other instances of serious skin 
reaction, including St evens -Johnson Syndrome (SJS), toxic epidermal necrolysis 
(TEN) and erythema multiforme, have been reported for DTG in clinical trials.  
 Hepatotoxicity accompanied by severe rash or systemic allergic reaction, 
including potentially life- threatening events , have been reported in individuals 
taking MVC.  Severe skin and hypersensitivity reactions including SJS and TEN 
have also been reported in individuals  taking MVC.  
 
Participants  with an isolated Grade 1 rash may continue study medication s at 
the site investi gator’s discretion.  The participant  should be advised to contact 
the site investigator immediately if there is any worsening of the rash, if any 
systemic signs or symptoms worsen, or if mucosal involvement develops. 
 
Participants  may continue study medicat ions for an isolated Grade 2 rash. 
However, study medications (and all other concurrent  medication(s) suspected in 
the site i nvestigator ’s causality assessment) should be permanently discontinued 
for any ≥ Grade 2 rash that is associated with an increase in ALT. The 
participant  should be advised to contact the site investigator immediately if rash 
fails to resolve (after more than 2  weeks), if there is any worsening of the rash, if 
any systemic signs or allergic symptoms develop, or if mucosal involvement develops.  
 
If the etiology of the rash can be definitely diagnosed as being unrelated to study medications and due to a specific medical event or a concomitant 
non- study medication, routine management should be performed and 
documentation of the diagnosis provided.  
 
Participants  should permanently discontinue study medications  (and all other 
concurrent medication(s) suspected in the site investigators causality 
assessment) for an isolated Grade 3 or 4 rash,  and the participant  will be 
followed  off study treatment , on study . Participants should be treated as 
clinically appropriate and followed until resolution of the AE.  
 
7.1.9 Suicidal Ideation 
 
Participants with HIV infection may occasionally present with symptoms of depression and/or suicidality (suicidal ideation or behavior). In addition, 
there have been some reports of depression and/or  suicidal ideation and 
behavior (particularly in patients with a pre- existing history of depression 
 51 A5324 
Final Version 2.0  
  08/25/17  
 
 or psychiatric illness) in some patients being treated with integrase 
inhibitors, including DTG. Therefore, it is appropriate to monitor participants for suicidality before and during treatment.  
 Participants should be monitored appropriately and observed closely for 
suicida l ideation and behavior or any other unusual changes in behavior. It 
is recommended that the investigator consider mental health consultation 
or referral for participants who experience signs of suicidal ideation or 
behavior.  
 
If the participant  expresses suicidal ideation or intent, the data will be captured 
as AEs. Any suicide thought or attempts that qualifies as an EAE will be reported 
using the standard EAE mechanism  (see section 11.4.2) . 
 
7.2 Additional Considerations for Participants  Infected with He patitis B V irus (HBV)  
 
Particular diligence should be applied in initiating or maintaining effective anti -HBV 
therapy (referring to treatment guidelines  such as  IAS) when starting DTG -based 
therapy in HBV co -infected individuals. Liver chemistry elevations  consistent with 
immune reconstitution syndrome have been observed in some HBV co -infected 
individuals  at the start of DTG therapy, particularly in the setting where anti -hepatitis 
therapy was withdrawn.  
 
Clinical trial and marketed use of 3TC, FTC and TDF have shown that some individuals 
with chronic HBV disease may experience clinical or laboratory evidence of recurrent 
hepatitis upon discontinuation of 3TC, FTC or TDF, which may have more severe 
consequences in individuals with decompensated liver disease. If 3TC, FTC , or TDF is 
discontinued in participants co- infected with HBV, periodic monitoring of both liver 
chemistry tests and markers of HBV replication should be considered. 
 
7.3 Pregnancy  
 
Pregnancy and pregnancy outcome will be recorded on the CRFs. Pregnancies 
that occur on study should be reported prospectively to The Antiretroviral Pregnancy Registry. More information is available at www.apregistry.com
. Phone: 
800-258-4263; Fax: 800 -800-1052. For studies conducted at sites outside the 
United States, report to The Antiretroviral Pregnancy Registry— Telephone: 910 -
679-1598; Fax: 44- 1628 -789-666 or 910 -256-0637.  
 
 Pregnancy Outcomes and Reporting  
 
The core team ( actg.corea5324@fstrf.org ) should be notified immediately if a 
participant  becomes pregnant after study entry. Study medications  must be 
discontinued and the underlying ART regimen continued at the discretion of the site 
investigator . Participants will come  in for a premature treatment discontinuation 
evaluation visit within 14 days after stopping study medications. Participants who 
choose to stay on study will continue to be followed on study/off study treatment, but will 
 52 A5324 
Final Version 2.0  
  08/25/17  
 
 not have blood drawn for PK studies  and stored plasma/PBMCs. They also will not have 
to complete the adherence questionnaire. 
 
If a woman has completed the study or chooses to discontinue from the study before the 
end of the pregnancy, then site staff should request permission to contact her regarding 
pregnancy outcomes at the end of pregnancy. If the information is obtained, pregnancy 
outcomes will be submitted on a CRF at the end of the pregnancy.  
 
7.4 Breastfeeding 
 
Breastfeeding is not allowed during the study.  
 7.5 Unblinding  
 
 Unblind ing can be requested in the following settings : 
• At any time that virologic failure  occurs if the primary provider is considering 
switching therapy and believes that the unblinded study medication  information 
will assist in choosing the next regimen.  
• For an  adverse event that leads to permanent discontinuation of one or both 
study medications only if the unblinded study medication information  will affect 
patient management.  
 Site should send  requests for unblinding to the core team ( actg.corea5324@fstrf.org
). 
Unblinding procedures will follow the ACTG Standard Operating Procedure for 
Unblinding Participants, which is  located on the ACTG website. At the time of the 
request, all data relevant to the medication substitution or virologic failure should have 
been entered into the ACTG database.  All discussion of unblinding should be limited to 
the actg.corea5324@fstrf.org  email  and should be carefully worded to prevent 
unblinding the team, if possible.  
 
7.6 Antiretroviral Therapy Changes 
 
Study participants should enter the study with the intention to continue on the 
same ART regimen.  Any changes to the ART regimen, other than TDF to TAF -
based regimens and RTV to COBI -based regimens, should be discussed with the 
A5324 core team in advance ( actg.corea5324@fstrf.org ). New regimens should not 
include ARVs on the prohibited medications list.  
  
8.0 CRITERIA FOR  DISCONTINUATION  
 8.1 Premature  Treatment Discontinuation  
• Pregnancy  or breastfeeding  
• Drug -related toxicity (see section 7.1) 
 53 A5324 
Final Version 2.0  
  08/25/17  
 
 • Requirement for prohibited concomitant medications (see section 5.4) 
• Request by  participant  to terminate treatment  
• Clinical reasons believed life -threa tening by the physician, even if not addressed in 
the toxicity section  of the protocol  
 
8.2 Premature Study Discontinuation 
• Participant  missed b oth week 24 and week 48 visits  
• Request by the participant  to withdraw  
• Request of the primary care provider if s/he thinks the study is no longer in the best 
interest of the participant  
• Participant  judged by the investigator to be at significant risk of failing to comply with 
the provisions of the protocol as to cause harm to self or seriously interfere with the 
validity of the study results  
• At the discretion of the IRB/ EC, FDA, NIAID, Office for Human Research Protections 
(OHRP),  other government agencies as part of their duties,  investigator, or industry  
supporter  
 
 9.0 STATISTICAL CONSIDERATIONS  
 9.1 General Design Issues  
 
A5324 is a randomized, placebo- controlled, double- blinded, phase IV clinical trial 
designed to compare changes in neurocognitive functioning at week 48 in Arm C ( MVC 
and DTG) to Arm B ( placebo for MVC  and DTG) and Arm A (placebo for MVC and 
placebo for DTG) in participants who have at least mild neurocognitive impairment, are 
on a stable ART , and have plasma HIV- 1 RNA < 50 copies/mL. In addition, a comparison 
of the ( Arm B: placebo for MVC and DTG) and ( Arm A: placebo for MVC and placebo for 
DTG ) arms will be conducted. A comparison of the safety and tolerability will be 
conducted as well. Eligible participants will be randomized to add one of the following 
to their existing ARV regimen:  
• Arm A: Placebo for MVC and Placebo for DTG  
• Arm B: DTG active d rug and Placebo for MVC  
• Arm C: MVC and DTG active drug s 
 
All participants  will be assessed at pre- entry, and then every 24 weeks for 96 weeks 
with a neurocognitive battery.  
 Limitations of the design include the fact that changes over time will be a function of both 
intervention effects, natural history, and practice effects that are common in 
neuropsychological studies. However, randomized treatment comparisons will be valid.   
 
 54 A5324 
Final Version 2.0  
  08/25/17  
 
 9.2 Outcome Measures  
 
9.2.1 Primary Outcome Measures  
 
The primary outcome  is the change in normalized composite neurocognitive test 
score at week 48 from pre -entry.  The normalized neurocognitive test score is 
defined as the average of z -scores on the following tests:  
 
Neurocognitive Test Battery for CRSs in the United States:  
a) Atten tion/Working Memory (Symbol Search  Trail Making A ) 
b) Speed of Information Processing (Stroop Word, Stroop Color, Digit 
Symbol)  
c) Executive Function (Trail Making B, Stroop Color/Word, Letter and Category Fluency)  
d) Verbal  Learning ( HVLT -R) 
e) Verbal Memory (Delayed  Recall – HVLT -R) 
f) Fine Motor Skills/Complex Perceptual (Grooved Pegboard Bilateral) 
g) Language/Premorbid Skills (WRAT- 4 Reading OR WAT for participants 
with Spanish as their primary language) 
 
Neurocognitive Test Battery for CRSs outside the United States:  
a) Attention/Working Memory (Color Trails 1)  
b) Speed of Information Processing (Digit Symbol)  
c) Executive Function (Color Trails 2, Category Fluency)  
d) Verbal Learning (HVLT -R) 
e) Verbal Memory (Delayed Recall – HVLT -R) 
f) Fine Motor Skills/Complex Perceptual (Grooved Pegboard Bilateral , 
Fingertapping Bilateral); Gross Motor (Timed Gait)  
g) IHDS  
 
For the assessment of neurocognitive impairment at baseline, weeks 24, 48, 
72, and 96, z -scores will be  calculated by subtracting a demographically 
appropriate (adjusted for age, race, sex, and years of education) norm and 
dividing by a demographically appropriate standard deviation. Normative data will be available from Heaton et al . [65, 66] and A5271 , and the best available 
normative dat a will be utilized. Functional change will be defined as a change on 
the IADL instrument: Best minus Now, summed across items 1 -16, where 
positive changes or increments reflect better functional capacity and negative changes or decrements reflect poorer functional capacity. Items with a 
 55 A5324 
Final Version 2.0  
  08/25/17  
 
 response of 8 (not applicable) or that  are missing will be excluded from the 
summation in both Best and Now.  
 
For assessment of change over time  in neurocognitive impairment , z-scores 
will be calculated by subtracting the z-scores of the two time points of 
interest .  
 
In addition, based on the z -scores, Global Deficit Scores (GDS) will be computed 
for the domains, and the total battery. The GDS emphasizes impairment, reduces minimal learning/practice  and has the advantage of reducing ‘sum to zero’ effects 
seen with counterbalancing positive and negative scores in a participant’s  
assessment. However, this approach does minimize the ability to observe subtle 
changes as scores are grouped into larger categories  [67].  
 
9.2.2 Secondary Outcome Measures  
 9.2.2.1  Treatment related AEs. 
 
9.2.2.2  Change of normalized composite neurocognitive test score at weeks 24, 72, and 96.  Change of normalized component neurocognitive test 
scores at weeks 24, 48, 72, and 96 will also be examined.  
 
9.2.2.3  Change in functional status scores based on the IADLs form at weeks 
24, 48, 72 , and 96.  
 
9.2.2.4  Change from baseline of peripheral blood  and CSF biomarkers at 
week 48.  
 
9.2.2.5  Plasma HIV -1 RNA less than 50 copies/mL at weeks 24, 48 , and 96.  
 
9.2.2.6  CD4+ T -cell counts and changes from baseline to weeks 24, 48 , and 
96. 
 
9.2.2.7  CD8+ T -cell counts and changes from baseline to weeks 24, 48 , and 
96. 
 9.2.2.8  Changes from baseline to week 48: residual viremia, cell -associated 
HIV-1 RNA/DNA/2 -LTR circles and SCA, T cell and monocyte 
activation.  
 9.3 Randomization and Stratification  
 
Eligible participants  will be randomized with equal probability to add to their existing 
ART either A rm A: placebo for MVC  and placebo for DTG, or Arm B: DTG  active drug 
and placebo for MVC , or Arm C: MVC and DTG  active drugs. Randomizati on will be 
stratified by CD4+ nadir (≤100 vs. > 100 cells/mm
3) and HAND severity (ANI vs. 
MND/ HAD). Since it is difficult to enroll participants with MND and HAD, strict balance 
 56 A5324 
Final Version 2.0  
  08/25/17  
 
 among the HAND stratification factors is not required. However, the distribution of HAND 
stratification factors will be closely monitored to ensure successful enrollment of participants  with MND and HAD (≥25%).  
 The CPE score of the current ART  (before intensification) will not be used as a 
stratification factor at randomization. Instead, it will be used as a continuous covariate in regression models to account for CNS penetrations of different ARTs .   
 
9.4 Sample Size and Accrual  
 
The primary outcome  of this study is the 48 -week change in normalized composite 
neuropsychological test score. For the primary analyses, all pairwise comparisons (ie , 
Arm B versus A rm A, A rm C versus Arm A, and Arm C versus A rm B) will be conducted 
to test for difference in the primary outcome . Based on previous results from A5235, we 
assume a standard deviation (SD) of 0.7 in the 48- week change in normalized 
neurocognitive test score.  
 
Standard 
Deviation  Number of 
Primary 
Comparisons  Nominal 
Power  Sample 
Size per 
Group  Adjusted 
Sample Size 
per Group  Total 
Sample 
Size Adjusted Total 
Sample Size  
0.6 2 0.80 28 33 84 99 
0.85 32 38 96 114 
0.90 36 42 108 126 
0.6 3 0.80 31 36 93 108 
0.85 34 40 102 120 
0.90 39 46 117 138 
0.7 2 0.80 38 45 114 135 
0.85 43 51 129 153 
0.90 49 58 147 174 
0.7 3 0.80 41 48 123 144 
0.85 46 54 138 162 
0.90 53 62 159 186 
0.8 2 0.80 49 58 147 174 
0.85 56 66 168 198 
0.90 64 75 192 225 
0.8 3 0.80 54 64 162 192 
0.85 61 72 183 216 
0.90 69 81 207 243 
 In the sample size calculation, the null hypothesis is that there is no difference in 
changes of neurocognitive functioning from baseline to week 48 across the treatment 
arms, while the alternative hypothesis is that the change of neurocognitive functioning is at least 0.5 higher for the (MVC and DTG ) arm. The Bonferroni correction has been 
applied to account for multiple comparisons between treatments. One interim analysis of 
 57 A5324 
Final Version 2.0  
  08/25/17  
 
 efficacy is planned in the middle of the study and the adjusted sample sizes assume a 
15% loss to follow- up. To achieve a power of 90%, we would expect a sample size of 62 
participants  per group for a total 186 participants on study. The team anticipates that 
the targeted sample size can be reached in around one year.  
 
A secondary objective of this study is to compare the changes in CSF biomarkers (eg, 
neopterin) between arms. Since CSF bio markers are measured through optional  LP 
procedures, data on CSF biomarkers will not be available for all participants in this 
study. Thus, it is of importance to provide power and sample size justification for this 
secondary objective as well. Using neopterin as an example and assuming a SD of 1.0 
from prior studies, we will need 17 participants per group to detect a mean difference of 
1.0 nmol/L with 80% power (based on a two- sample t -test). In HIV -infected individuals  
on suppressive HAART, CSF neopterin remains persistently elevated to a median 6.3 nmol/L, while normal levels in HIV uninfected individuals are between 4.3 and 5.3 
nmol/L.  Reducing the CSF neopterin by 1.0 nmol/L would lower this marker of 
macrophage  immune activation to levels close to levels in HIV negative individuals. The 
figure below also shows the power curves under more  conservative SD assumptions (ie , 
1.5 and 2.0).  
 
 
Figure: Power Plots for Comparing CSF Neopterin Levels at Week 48  
 
 58 A5324 
Final Version 2.0  
  08/25/17  
 
 9.5 Monitoring  
 
Three types of monitoring reviews will be conducted based on reports prepared by study 
statisticians and/or data manager and/or lab data managers. They are routine monitoring 
reviews, data quality reviews, and reviews by Study Monitoring Committee (SMC) of the 
Neurology Collaborative Science Group.  
 
Routine monitoring reviews will monitor proper execution of the protocol. The study core 
team will receive monthly reports on accrual, study status, screening failures, and 
missing forms and outcomes. The accrual report will also be distributed to the whole 
protocol team. Quarterly toxicity reports and biannual data availability reports will 
be sent to the core team.  
 The DAIDS clinical representative will review and assess EAE reports for potential impact on the study participant safety and protocol conduct as per DAIDS 
policies, guidance documents, and SOPs as applicable. Additionally, the DAIDS 
clinical representative will review aggregated adverse event summaries by blinded 
treatment arm prepared every 6 months  by the Statistical and Data Anal ysis 
Center (SDAC). 
 
In addition, the team anticipates enrollment of  8 participants  in each arm who  
consent to voluntary  LP when the study has accrued half the required participants . If 
this is not reached, the team will focus on recruitment/enrollment ef forts at the sites that 
have experience performing LPs. 
 
Data quality reviews will  ensure all required samples are collected and tracked, and 
corresponding outcomes are entered in the study database. Eligibility verification will be checked monthly. HIV -1 RNA virology data and pregnancy will be checked every three 
months.  
 There are three types of Neurology Collaborative Science Group SMC reviews: one 
interim analysis review, routine SMC reviews, and unexpected safety events reviews. 
The purpose of the inte rim analysis review is to re -evaluate sample size and to assess 
efficacy of treatment arms. This happens in the middle of the study when about 50% of 
participants are enrolled and followed -up for 48 weeks . 
 Observed SD for the primary endpoint will be compared to the assumed value (SD=0.7) 
to determine the necessity of sample size adjustment. Also two steps will be conducted 
for monitoring efficacy.  
• Step 1: Pairwise comparisons will be conducted for three blinded treatment arms. Based on the repeated confidence intervals (RCIs) method and Bonferroni 
correction, we will use threshold p- value 0.0007 for each comparison, which 
correspond to a 99.93% CI.   
• Step 2: If none of the pairwise comparisons shows significance, then we will 
continue with all three arms; If any pairwise comparison is significant, then we 
 59 A5324 
Final Version 2.0  
  08/25/17  
 
 predicted interval plots (PIPS) method [ 68, 69] will be used to see if we can stop 
the arm/study early and claim efficacy. 
 
Routine SMC reviews will  assess the study progress via reviewing accrual, study stat us, 
screening failures, toxicity, etc. This will happen at least annually after enrolling the first participant  as required by NIH guidelines. Unexpected safety event reviews will  
report any unexpected safety events to the Neurology Collaborative Science Group SMC 
when safety concerns are raised by the core team.  
 NOTE: Please refer to the A5324 study monitoring plan for details of the monitoring 
process or any updates.  
 
9.6 Analyses  
 
9.6.1 Primary Analysis  
 
The ITT principle (ie, all randomized participants  will be included in the primary 
analyses) will be used for the primary analysis to compare the changes of 
neurocognitive functioning from baseline to week 48. Multiple imputation methods will be used to handle missing values. Sensitivity analyses will be 
conducted under different assumptions to assess the impact and informativeness 
of missing data. In addition, a per -protocol analysis will also be conducted by 
restricting the analysis to participants who adhere perfectly to the instructions in 
the study protocol. The Kolmogrov -Smirnov test will be employed to check 
whether the primary outcome is normally distributed. If the normality assumption 
is not rejected, the two- sample t -test will be used for pairwise comparisons 
between any two arms. Otherwise, the nonparametric analogue of the two-
sample t -test (ie, Wilcoxon rank -sum test) will be used as an alternative. The test 
will be stratified by CD4+ nadir (≤100 vs. >100 cells/mm
3) and HAND severity 
(ANI vs. MND/HAD). All pairwise comparisons will be conducted among the three study arms.  
 
9.6.2 Secondary Analyses  
 
9.6.2.1  The Cox proportional hazards model will be applied to compare the time to discontinuation of medication due to AEs. Logistic regression models 
will be used to characterize the proportion of  participants  with Grade 3 
or Grade 4 clinical AEs or laboratory abnormalities.  
 
9.6.2.2  The Kruskal -Wallis test will be employed to compare changes in 
neurocognitive functioning across the three treatment arms at weeks 
24, 72 , and 96. All pairwise comparisons between two treatment arms 
will be conducted based  on the Wilcoxon rank -sum test.  
 
9.6.2.3  Similar to the analyses for neurocognitive functioning, changes in 
functional status scores at weeks 24, 48, 72 , and 96 will also be 
compared among treatment arms using the Kruskal -Wallis test (for 
 60 A5324 
Final Version 2.0  
  08/25/17  
 
 overall comparisons across the three treatment arms) and the Wilcoxon 
rank-sum test (for pairwise comparisons between two treatment arms). 
 
9.6.2.4  Wilcoxon signed- rank test will be used to assess the changes from 
baseline of peripheral blood biomarkers and CSF biomarkers at week 
48. Comparisons of changes in these biomarkers between any two 
treatment arms will be conducted through Wilcoxon rank -sum test . 
 
9.6.2.5  Association between peripheral blood  and CSF biomarkers and 
neuropsychological performance will be estimated  at each visit  using 
the Spearman correlation.  
 9.6.2.6  For each treatment arm, the proportions of participants with HIV -1 
RNA less than 50 copies/mL and their associated 95% CIs will be 
plotted over time . Logistic regression models will be used to compare 
the odds corresponding to the proportions across the treatment arms at weeks 24, 48, and 96.  
 9.6.2.7  Average CD4+/CD8+ counts and their associated 95% CIs will be plotted over time for each treatment ar m. Changes in CD4+/CD8+ 
counts from baseline to weeks 24, 48, and 96 will be compared across 
treatments arms through Wilcoxon rank -sum test.  
 9.6.2.8  Spearman correlation will be used to determine the association between changes in blood immunologic markers and changes in neurocognitive 
function from baseline to week 48.  
 9.6.2.9  Spearman correlation will be used to explore the relationship between 
changes in CCR5 ligand levels (MIP -1β) and inflammatory markers 
changes  from baseline to week 48 . Scatterplots  will display 
relationships.  
 
9.6.2.10  Wilcoxon rank -sum test will be used to compare Arm A and Arm B to 
assess the effect of DTG intensification on virologic changes. 
Association between the vriologic changes and changes in 
neurocognitive function from baseline to week 48 will be examined 
using the Spearman correlation.  
 9.6.2.11  Similar to the primary analysis, the ITT principle will be used to 
compare the changes of GDS scores from baseline to week 48. All 
pairwise comparisons will be conducted among the  three study 
arms.  
 9.6.2.12  Subgroup analyses will be performed for the primary outcome in 
each participating country. In presence of significantly different 
results by country, the changes of neurocognitive functioning will be compared by adjusting for country effects.  
 61 A5324 
Final Version 2.0  
  08/25/17  
 
  
 10.0 PHARMACOLOGY PLAN  
 
MVC is a CCR5 co -receptor antagonist that is given twice daily. In phase II and III 
studies (MOTIVATE -1 and MOTIVATE -2), MVC demonstrated potent ARV activity and 
good tolerability in treatment -experienced participants  [28, 29]. Importantly, it was 
noted, and confirmed in the phase II and III studies that MVC in combination with other 
ARV agents resulted with a significant  reduction in viral load in adult participants  with 
no detectable CXCR4- using plasma HIV -1 who were experiencing virologic failure on 
their current ARV regimen with  multi -resistant virus. In addition, the CD4+ cell count 
was increased to a significantly greater extent with MVC compared with placebo in these studies. The most frequently seen AEs in the phase II and III studies are diarrhea (8-
10%), nausea (6%), headache (2 -5%), fatigue (3- 4%), upper respiratory tract infection 
(4-5%), and fever (2- 6%). The other common AEs (>8% incidence) include cough, 
pyrexia, rash , and dizziness. Hepatotoxicity accompanied by severe rash or systemic 
allergic reaction including potentially life- threatening events has been reported.  
 MVC is a substrate of CYP3A and P -gp, inhibitors and inducers of these 
enzymes/transporters influence MVC pharmacokinetics  (PK). A dosage of 150 mg BID is 
recommended when given with potent CYP3A inhibitors, including HIV -1 protease 
inhibitors, such as LPV/r, DRV /r, saquinavir/ritonavir ( SQV/r ), and ATV/r, as well as 
ketoconazole that significantly increase the C
max and AUC of MV C, whereas 300 mg BID 
of MVC is recommended with concurrent use of NRTIs, TPV/r, NVP, DTG , and other 
drugs that are not potent CYP3A inhibitors or inducers. When MVC is coadminister ed 
with potent CYP3A inducers, eg,  RIF, ETR and EFV, there is a significant reduction in 
MVC C max, AUC, and C min. As a result, it is recommended that when used with these 
agents, 600 mg of MVC should be given BID.  Data from several studies with a small sample size, which evaluated MVC 
concentrations in CSF, suggest that MVC achieves therapeutic concentrations (EC
50-
EC 90) in the CSF even though MVC plasma concentrations and physiochemical 
characteristics are poor predictors of its CNS distribution [ 21, 70, 71, 72]. While the 
trough MVC plasma concentration ranged from 94.9 to 337 ng/mL, the mean CSF 
concentrat ion ranged from 2.4 to 7.5 ng/mL. The mean CSF:plasma ratio was ~0.02. 
Small increases in cerebral metabolite markers of neuronal integrity were reported in 12 
participants  treated with MVC, and these changes associated with MVC plasma trough 
concentrations  [71].  
 
10.1 Pharmacology Objectives  
 
10.1.1 Investigate DTG  and MVC  plasma concentrations and determine PK parameters 
including area- under -the curve and clearance.  
 
10.1.2 Investigate the relationship between plasma PK and CSF concentrations for DTG  
and MVC  including CSF: plasma ratio.  
 
 62 A5324 
Final Version 2.0  
  08/25/17  
 
 10.1.3 Investigate associations between DTG  and/or MVC plasma and CSF 
concentrations in a multivariate analysis including:  
a) Changes in neurocognitive testing scores . 
b) Self-reported adherence . 
c) C hanges in peripheral blood and CSF biomarkers.  
 
10.2 Pharmacology Study Design 
 
Only DTG and MVC will be measured based on the assumption that the neurocognitive benefits of intensification are directly related to DTG and/or MVC.  
 10.2.1  A single abbreviated plasma PK study at week 12 in all participants including a 
pre-dose sample and observed dose. Two  additional samples at 2 and 4 hours 
after the dose  at week 12.  
 
If DTG/placebo for DTG  is taken once daily in the evening:  
• At least 3 days prior to the week 12  PK visit , the evening DTG/placebo for 
DTG  dose should be converted to a morning dose. Participants  should 
be reminded at least 5 days prior to the week 12 PK visit to convert the evening DTG/placebo for DTG dose to a morning dose at least 3 days 
prior to the visit.  Participants should be instructed to hold their morning 
doses of  DTG /placebo for DTG  and MVC/placebo for MVC  on the day of 
the week 12 PK visit and the doses will be given in the clinic after the pre -
dose sample has been obtained.    
• If the participant  does not convert DTG /placebo for DTG  to morning 
dosing, there will b e no observed dose of DTG/placebo for DTG . The 
participant  should still hold the morning dose of MVC/placebo for MVC  
and the dose will be given in the clinic after the pre- dose sample is 
obtained. The PK sampling will remain the same.  
 
If DTG/placebo for DTG is taken twice daily:  
• Participants  should be instructed to hold their morning doses of 
DTG/placebo for DTG  and MVC/placebo for MVC  on the day of the week 
12 PK visit. The doses will be given in the clinic after the pre -dose sample 
has been obtained.  
 
10.2.2  Repeated trough samples at weeks 24 and 48.  
 
Participants  taking DTG/placebo for DTG  once daily in the evening should be 
instructed to convert to morning dosing as descri bed in section 10 .2.1.  
Participants  should also be instructed to hold their morning doses of 
DTG/placebo for DTG  and MVC/placebo for MVC  as described in section 1 0.2.1. 
The doses will be given in the clinic after the PK sample has been obtained.  
 63 A5324 
Final Version 2.0  
  08/25/17  
 
 10.2.3  CSF concentrations of MVC and DTG in participants who consent to  LP (see 
section 6.3.18). 
 
10.3 Primary and Secondary Data, Modeling, and Data Analysis  
  Using PK models derived from previous intensive PK data  [73, 74], participants’ limited 
drug concentrations will be used to estimate key PK parameters (exposure, as indicated 
by area under the concentration curve, AUC and clearance, Cl/F). The population PK analyses  incorporating plasma and CSF data will be based on nonlinear mixed effects 
models. These participant  level estimates will then be used for comparison of drug  
exposure between participants  with and without neurocognitive changes (with non-
parametric tests and with PK models). Pharmacodynamic analyses will evaluate the relationship between the model derived participant -specific estimates of PK parameters 
(AUC and Cl/F) and neurocognitive changes.  
 
10.4 Anticipated Outcomes  
 We anticipate that participants  in A5324 will enter the study on a variety of ART 
regimens . These participants will receive the recommended doses of DTG  and MVC, 
as per t ables A and B in section 5.1.1 , but ther e will be a wide range of individual 
plasma and CSF exposures based on expected interpatient variability. The proposed 
clinical pharmacology objectives will provide PK data and strengthen the multivariate 
analysis that will help identify specific covariates that are associated with the primary outcomes as well as provide an additional adherence confirmation.  
 
 
11.0 DATA COLLECTION AND MONITORING AND ADVERSE EVENT  REPORTING 
 11.1 Records to Be Kept  
 
CRF will be made available to sites for data entry. Partic ipants must not be identified 
by name on any data submitted to the DMC . Participants  will be identified by the 
patient identification number (PID) and study identification number (SID) provided by the ACTG DMC  upon randomization. 
 
Participant s’ background ART will be recorded at randomization on randomization logs.  
 
11.2 Role of Data Manageme nt 
 
11.2.1 Instructions concerning entering  study data on CRFs will be provided by the 
ACTG DMC . Each CRS  is responsible for keying the dat a in a timely fashion. 
 11.2. 2 It is the responsibility of the ACTG DMC  to assure the quality of computerized 
data for each ACTG study. This role extends from protocol development to generation of the final study databases.  
 
 64 A5324 
Final Version 2.0  
  08/25/17  
 
 11.3 Clinical Site Monitoring and Record Availability  
 
11.3.1 Site monitors under contract to the NIAID will visit participating clinical research 
sites to review the individual participant  records, including consent forms, CRFs, 
supporting data, laboratory specimen records, and medical records (physicians’ progres s notes, nurses’ notes, individuals’ hospital charts), to ensure protection 
of study participants, compliance with the protocol, and accuracy and 
completeness of records. The monitors also will inspect sites’ regulatory files to 
ensure that regulatory requirements are being followed and sites’ pharmacies to 
review product storage and management. 
 
11.3.2 The site investigator will make study documents ( eg, consent forms, drug  
distribution forms, CRFs) and pertinent hospital or clinic records readily availabl e 
for inspection by the local IRB/EC , the site monitors, the FDA,  the NIAID, the 
OHRP, and the industry  supporters or designee for confirmation of  the study 
data.  
 
11.4 Expedited Adverse Event Reporting to DAIDS  
 
11.4.1  Adverse Event Reporting to DAIDS  
 
Requirements, definitions and methods for expedited reporting of AEs are 
outlined in Version 2.0 of the DAIDS EAE Manual, which is available on the RSC website at  
http:// rsc.tech- res.com/clinical- research- sites/safety -
reporting/manual . 
 The DAIDS Adverse Events Reporting System (DAERS), an internet -based 
reporting system, must be used for expedited AE reporting to DAIDS. In the event of system outages or technical difficulties, expedited AEs may be submitted via the DAIDS EAE Form. For  questions about DAERS,  please contact 
DAIDS -ES (now part of the NIAID Clinical Research Management System)  at 
CRMSsupport@niaid.nih.gov
. Site  queries may also be sent  from within the 
DAERS application itself.  
 Sites where DAERS has not been implemented will submit expedited AEs by 
documenting the information on the current DAIDS EAE Form. This form is  
available on the RSC website at 
http://rsc.tech- res.com/clinical -research-
sites/safety- reporting/manual . For questions about EAE reporting, please 
contact the RSC ( DAIDSRSCSafetyOffice@tech -res.com ). 
 
11.4.2  Reporting Requirements for this Study  
 
• The SAE  Reporting Category, as defined in Version 2.0 of the DAIDS EAE 
Manual, will be used for this study.  
 
 65 A5324 
Final Version 2.0  
  08/25/17  
 
 • The study agents for which expedited reporting are required  are: 
− MVC and placebo for MVC   
− DTG and placebo for DTG 
 
• In addition to the EAE Reporting Category identified above, other AEs 
that must be reported in an expedited manner are:  
− Symptomatic or asymptotic AST/ALT and bilirubin elevations that result in discontinuation of study medications  
− Suicidal  thoughts or attempts that meet the EAE reporting 
category  
 
11.4.3  Grading Severity of Events  
 
The Division of AIDS Table for Grading the Severity of Adult and Pediatric AEs (DAIDS AE Grading Table), Version 2.1, March 2017 , must be used and is 
available on the DAIDS RSC w ebsite at 
http://rsc.tech -res.com/clinical -
research- sites/safety -reporting/daids -grading -tables . 
 
11.4.4  Expedited AE Reporting Period 
 
• The expedited AE reporting period for this study is per the EAE manual.  
 
• After the protocol -defined AE reporting period, unless otherwise noted, only 
suspected, unexpected serious adverse reactions (SUSARs), as defined in 
Version 2.0 of the EAE Manual, will be reported to DAIDS if the study staff become aware of the events on a passive basis (from publicly available 
information).  
 
 
12.0 PARTICIPANTS  
 12.1 Institutional Review Board (IRB) Review and Informed Consent  
 
This protocol and the informed consent document (Appendix I) and any subsequent 
modifications will be reviewed and approved by the IRB or ethics committee responsible 
for oversight of the study. A signed consent form will be obtained from the participant  
(or legally authorized representative, ie, a person with power of attorney to consent to 
participation in a clinical trial on behalf of a participant  who cannot provide informed 
consent). The consent form will describe the purpose of the study, the procedures to be followed, and the risks and benefits of participation. A copy of the consent form will be given to the participant  or legally authorized representative , and this fact will be 
documented in the participant’s record.  The IRB and site must comply with state and 
local laws regarding legally authorized representatives.  
 
 66 A5324 
Final Version 2.0  
  08/25/17  
 
 12.2 Participant  Confidentiality  
 
All laboratory specimens, evaluation forms, reports , and other records that leave the site 
will be identified by coded number only to maintain participant  confidentiality. All 
records will be kept locked. All computer entry and networking programs will be done 
with coded numbers only. Clinical information will not be released without written 
permission of the participant , except as necessary for monitoring by the ACTG, 
IRB/EC, FDA,  NIAID, OHRP,  other government agencies  as part of their duties , or the 
industry  supporter or designee.   
 
12.3 Study Discontinuation 
 
The study may be discontinued at any time by the ACTG, IRB/EC, FDA,  NIAID, OHRP, 
industry  supporter, or other  government  agencies as part of their duties to ensure that 
research participants  are protected.  
  
13.0 PUBLICATION OF RESEARCH FINDINGS  
 Publication of the results of this trial will be governed by ACTG policies . Any 
presentation, abstract, or  manuscript will be made available for review by the industry  
supporter prior to submission.  
  
14.0 BIOHAZARD CONTAINMENT  
 As the transmission of HIV and other blood- borne pathogens can occur through contact 
with contaminated needles, blood, and blood products, appropriate blood and secretion 
precautions will be employed by all personnel in the drawing of blood and shipping and handling of all specimens for this study, as currently recommended by the Centers for 
Disease Control and Prevention and the National Institutes of Health.  
 All dangerous goods and materials, including diagnostic specimens and infectious 
substances, must be transported using packaging mandated by CFR 42 Part 72. Please 
refer to instructions detailed in the International Air Transport  Association (IATA) 
Dangerous Goods Regulations.   
 
 
 
 67 A5324 
Final Version 2.0  
  08/25/17  
 
 15.0 REFERENCES  
 
1.  Robertson K, Smurzynski M, Parsons T, et al. The prevalence and incidence of 
neurocognitive impairment in the HAART era. AIDS 2007;21:1915 -21. 
 
2.  Heaton RK, Clifford DB, Franklin DR Jr, et al.; CHARTER Group. HIV -associated 
neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75:2087- 96.  
 
3.  Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite 
long- standing suppression of viremia.  AIDS 2010;24:1243- 50. 
 4.  Robertson K, Jiang H, Kumwenda J, et al. Improved neuropsychological and 
neurological functioning across three antiretroviral regimens in diverse resource-
limited settings: AIDS Clinical Trials Group Study A5199, the International Neurological Study. Clin Infect Dis 2012;55:868- 76. 
 5.  Robertson K, Kumwenda J, Supparatpinyo K, et al. A multinational study of 
neurol ogical performance in antiretroviral therapy- naïve HIV -1-infected persons in 
diverse resource -constrained settings. J Neurovirol 2011;17:438- 47. 
 6.  Robertson K, Liner J, Heaton R. Neuropsychological assessment of HIV -infected 
populations in international  settings. Neuropsychol Rev 2009;19:232- 49. 
 
7.  Robertson K, Jiang H, Evans SR, et al. International neurocognitive normative study: neurocognitive comparison data in diverse resource- limited settings: AIDS 
Clinical Trials Group A5271. J Neurovirol 2016;22:472- 8. 
 
8.  Navia BA, Dafni U, Simpson D, et al. A phase I/II trial of nimodipine for HIV- related 
neurologic complications.  Neurology 1998;51:221 -8. 
 9.  Nakasujja N, Miyahara S, Evans S, et al. Randomized trial of minocycline in the 
treatment of HIV -associated cognitive impairment.  Neurology 2013;80:196 -202. 
 10. Schifitto G, Zhang J, Evans SR, et  al.; ACTG A5090 Team. A multicenter trial of 
selegiline transdermal system for HIV- associated cognitive impairment.  Neurology 
2007;69:1314 -21. 
 
11. Ellis RJ, Moore DJ, Childer s ME et al.: The CHARTER Group. Progression to 
neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 
2002;59:923 -8. 
 
12. Liner J, R Meeker, Robertson K. CNS toxicity of antiretrovirals [Abstract 435] . In: 17th 
Conference on Retroviruses & Opportunistic Infections ; February 16 -19, 2010;  San 
Francisco, CA . 
 
 68 A5324 
Final Version 2.0  
  08/25/17  
 
  
13. Marra CM, Zhao Y, Clifford DB, et al. AIDS Clinical Trials Group 736 Study Team. 
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV -1 RNA and 
neurocognitive performance.  AIDS 2009;23:1359 -66. 
 14. Hagberg L, Cinque P, Gisslen M, et al. Cerebrospinal fluid neopterin: an informative 
biomarker of central nervous system immune activation in HIV -1 infection. AIDS Res 
Ther 2010;7:15.  
 15. Yilmaz A , Price RW , Spudich S , Fuchs D , Hagberg L, Gisslén M . Persistent intrathecal 
immune activation in HIV -1-infected individuals on antiretroviral therapy. J Acquir 
Immune Defic Syndr  2008;47:168 -73. 
 16. Letendre S, Marquie- Beck J, Capparelli E, et al. Validation of the CNS Penetration-
Effectiveness rank for quantifying antiretroviral penetration into the central nervous 
system. Arch Neurol 2008;65:65 -70. 
 17. Letendre SL, Mills AM, Tashima KT, et al ; Extended ING116070 study team. 
ING116070: A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV -1-infected, antiretroviral therapy -naive subjects. Clin Infect Dis 
2014;59:1032 -7.  
 18. Letendre S, McClernon D, Ellis R, et al.; CHARTER Group. Persistent  HIV in the central 
nervous system during treatment is associated with worse ART penetration and cognitive impairment  [Abstract 484b] . In: 17th Conference on Retroviruses and 
Opportunistic Infections ; February 16- 19, 2010 ; San Francisco , CA. 
 19. Letendre S, FitzSimons C, Ellis R, et al.; CHARTER Group. Correlates of CSF  viral 
loads in 1,221 volunteers of the CHARTER Cohort [Abstract 172] . In: 17th Conference 
on Retroviruses and Opportunistic Infections ; February 16- 19, 2010 ; San Francisco, CA . 
 
20. Cysique, LA, Vaida, F, Letendre, S, et al. Dynamics of cognitive change in  impaired HIV -
positive patients initiating antiretroviral therapy. Neurology 2009;73:342 -8. 
 
21. Tiraboschi JM, Niubo J, Curto J, Podzamczer D. Maraviroc concentrations in cerebrospinal fluid in HIV -infected patients. J Acquir Immune Defic Syndr 2010;55:606 -9. 
 22. Melica G, Canestri A, Peytavin G, et al. Maraviroc -containing regimen suppresses HIV 
replication in the cerebrospinal fluid of patients with neurological symptoms. AIDS 2010;24:2130 -3. 
 23. Sauzullo I, Lichtner M, Mengoni F, et al. Effect in vitro of CCR5 antagonists on innate immune system: maraviroc inhibits the migration of neutrophils, macrophages, and DC 
[Abstract 512] . In: 17th Conference on Retroviruses and Opportunistic Infections ; 
February 16- 19, 2010 ; San Francisco , CA. 
 
 69 A5324 
Final Version 2.0  
  08/25/17  
 
  
24. Hatano H , Strain MC , Scherzer R , et al. Increase in 2- long terminal repeat circles and 
decrease in D -dimer after raltegravir intensification in patients with treated HIV i nfection: 
a randomized, placebo- controlled trial. J Infect Dis  2013;208:1436- 42. 
 
25. Saag M, Goodrich J, Fätkenheuer G, et al. A double- blind, placebo- controlled trial 
of maraviroc  in treatment -experienced patients infected with non- R5 HIV -1. J Infect Dis 
2009;199:1638 -47.  
 
26. Saag M, Heera J, Goodrich J , et al. Reanalysis of the MERIT study with the enhanced 
Trofile assay [Abstract H -1232a] . In: 48th Inte rnational Conference on Antimicrobial 
Agents and Chemotherapy 2008;  October 25- 28, 2008;  Washington, DC.  
 
27. Sierra -Madero J, Di Perri G, Wood R, et al. Efficacy and safety of maraviroc versus 
efavirenz, both with zidovudine/lamivudine: 96 -week results fro m the MERIT study. HIV 
Clin Trials 2010;11:125 -32. 
 
28. Gulick RM, Lalezari J, Goodrich J, et al. MOTIVATE Study Teams. Maraviroc for 
previously treated patients with R5  HIV-1 infection. N Engl J Med 2008;359:1429- 41. 
 
29. Fätkenheuer G, Nelson M, Lazzarin A, et al. MOTIVATE 1 and 2 Study Teams. 
Subgroup analyses of maraviroc in previously treated R5 HIV -1 infection. N Engl J Med 
2008;359:1442 -55. 
 
30. Jubb B, Lewis M, Simpson P, et al. CCR5- tropic resistance to maraviroc is uncommon 
even among patients on functional maraviroc monotherapy or with ongoing low -level 
replication. In: 16th Conference on Retroviruses and Opportunistic Infections ; February 
8-11, 2009; Montreal, Canada. 
 31. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006; 57:619 -27. 
 32. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase 
inhibitor dolutegravir. Antimicrob Agents Chemother 2012;56:1627 -9. 
 33. Raffi F, Rachlis A, Stellbrink HJ, et al. Once -daily dolutegravir versus raltegravir in 
antiretroviral -naive adults with HIV -1 infection: 48 week results from the randomised, 
double- blind, non- inferiority SPRING- 2 study. Lancet 2013 ;381:735 -43. 
 34. Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate dolutegravir's effect on 
renal function via measurement of iohexol and para- aminohippurate clearance in healthy 
subjects. Br J Clin Pharmacol 2012 ;75:990 -6. 
 35. Van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in  
combination therapy in antiretroviral -naïve adults with HIV: planned interim 48 week 
results from SPRING -1, a dose- ranging, randomised, phase 2b trial. Lancet Infect Dis 
2012;12:111– 18. 
 70 A5324 
Final Version 2.0  
  08/25/17  
 
  
 
36. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir plus Abacavir –Lamivudine for the 
Treatment of HIV -1 Infection. N Engl J Med 2013;369:1807- 18. 
 37. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of 
S/GSK1349572, a next -generation HIV integrase inhibitor. Antimicrob Agent s 
Chemother 2011;55:813 -21. 
 38. Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting 
severity of central nervous system injury. Neurocrit Care 2007;6:121 -38. 
 39. Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M.  Early 
neurobehavioural outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999;30:1190– 5. 
 
40. Walz R, Portela LV, Tort AB, et al. Serum S100B levels in patients with HTLV -I 
associated myelopathy/tropical spastic  paraparesis. Neurology 2000;54:2021– 2. 
 
41. Schenatto CB, Xavier RM, Bredemeier M, et al. Raised serum S100B protein levels in neuropsychiatric lupus. Ann Rheum Dis  2006;65:829- 31. 
 42. Stanley LC, Mrak RE, Woody RC, et al. Glial cytokines as neuropathogenic factors in 
HIV infection: pathogenic similarities to Alzheimer’s disease. J Neuropathol Exp Neurol 
1994;53:231 -38. 
 
43. Pemberton LA , Brew BJ . Cerebrospinal fluid S- 100beta and its relationship with AIDS 
dementia complex. J Clin Virol 2001;22:249- 53. 
 
44. Woods SP , Iudicello JE , Dawson MS , Weber E , Grant I, Letendre SL , HIV 
Neurobehavioral Research Center (HNRC) Group. HIV -associated deficits in action 
(verb) generation may reflect astrocyt osis. J Clin Exp Neuropsychol  2010;32:522- 7. 
 
45. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of 
system ic immune activation in chronic HIV infection. Nat Med 2006;12:1365- 71. 
 
46. Wang H, Sun J, Goldstein H. Human immunodeficiency virus type 1 infection increases 
the in vivo capacity of peripheral monocytes to cross the blood- brain barrier into the 
brain and the in vivo sensitivity of the blood- brain barrier to disruption by 
lipopolysaccharide. J Virol 2008;82:7591 -600. 
 47. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PloS One 2008;3:e2516.  
 48. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. 
JAMA 2012;308:379 -86. 
 
 71 A5324 
Final Version 2.0  
  08/25/17  
 
  
49. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams K. Elevated 
sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment 
in HIV infection. AIDS 2013;27:1387 -95. 
 50. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and Coagulation Biomarkers and 
Mortality in Patients with HIV Infection. PLoS Med 2008;5:e203. 
 51. Hunt PW,  Shulman NS, Hayes TL, et al. The immunologic effects of maraviroc 
intensification in treated HIV -infected individuals with incomplete CD4+ T -cell recovery: a 
randomized trial. Blood 2013;121:4635 -46. 
 52. Wirleitner B, Schroecksnadel K, Winkler C, Fuchs D.  Neopterin in HIV -1 infection. Mol 
Immunol 2005;42:183 -94. 
 53. Dhillon NK, Williams R, Callen S, Zien C, Narayan O, Buch S. Roles of MCP -1 in 
development of HIV- dementia. Front Biosci 2008;13:3913- 18. 
 
54. Sevigny JJ, Albert SM, McDermott MP, et al. An evaluation of neurocognitive status and 
markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 2007;64:97- 102. 
 55. Monteiro de Almeida S, Letendre S, Zimmerman J, Lazzaretto D, McCutchan A, Ellis R. 
Dynamics of monoc yte chemoattractant protein type one (MCP -1) and HIV viral load in 
human cerebrospinal fluid and plasma. J Neuroimmunol 2005;169:144 -52. 
 56. Mankowski JL, Queen SE, Clements JE, Zink MC. Cerebrospinal fluid markers that 
predict SIV CNS disease. J Neuroimmunol 2004;157:66- 70. 
 57. Cinque P, Bestetti A, Marenzi R, et al. Cerebrospinal fluid interferon -gamma -inducible 
protein 10 (IP -10, CXCL10) in HIV -1 infection. J Neuroimmunol 2005;168:154- 163. 
 58. Shacklett BL, Cox CA, Wilkens DT, et al. Increased adhesion molecule and chemokine 
receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV -1 infection. J 
Infect Dis 2004;189:2202 -12. 
 59. Gisslen M, Rosengren L, Hagberg L, Deeks SG, Price RW. Cerebrospinal fluid signs of 
neuronal damage after antiretroviral treatment interruption in HIV -1 infection. AIDS Res 
Ther 2005;2:6.  
 
60. Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL) -- a marker of 
active HIV -related neurodegeneration. J Neurol 2007;254:1026 -32. 
 61. Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated 
cerebrospinal fluid neurofilament light protein concentrations predict the development of 
AIDS dementia complex. J Infect Dis 2007;195:1774- 8. 
 
 72 A5324 
Final Version 2.0  
  08/25/17  
 
  
62. Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ , Gisslen M. Antiretroviral 
treatment reduces increased CSF neurofilament protein (NFL) in HIV -1 infection. 
Neurology 2007;69:1536 -41. 
 
63. Gisslen M, Krut J, Andreasson U, et al. Amyloid and tau cerebrospinal fluid biomarkers 
in HIV infection. BMC Neurol 2 009;9:63.  
 
64. Antinori A , Arendt G , Becker JT , et al. Updated research nosology for HIV- associated 
neurocognitive disorders. Neurology  2007;69:1789- 99. 
 
65. Heaton RK, Miller SW, Taylor MJ, Grant I. Revised Comprehensive Norms for an 
Expanded Halstead -Reitan Battery: D emographically Adjusted 
Neuropsychological Norms for African American and Caucasian Adults. Lutz, FL: 
Psychological Assessment Resources, Inc.; 2004.  
 
66. Heaton RK, Grant I, Matthews CG. Comprehensive N orms for an Expanded Halstead-
Reitan Battery: D emographic Corrections, Research Findings, and C linical Applications. 
Odessa, FL: Psychol ogical Assessment Resources, Inc. ; 1991.  
 
67. Carey CL, Woods SP, Gonzalez R, et al.; HNRC Group. Predictive validity of global 
deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp 
Neuropsychol 2004;26:307- 19. 
 68. Evans SR,  Li L, Wei LJ. Data monitoring in clinical trials using prediction. Drug Inf J 
2007;41:733 -42. 
 
69. Li L, Evans SR, Uno H, Wei LJ. Predicted interval plots: a graphical tool for data 
monitoring in clinical trials. Stat Biopharmaceut Res 2009;1:348- 55. 
 
70. Croteau D, Best BM, Letendre S, et al .; CHARTER Group. Lower than expected 
maraviroc concentrations in cerebrospinal fluid exceed the wild- type CC chemokine 
receptor 5 -tropic HIV-1 50% inhibitory concentration. AIDS 2012;26:890- 3. 
 
71. Garvey L, Nelson M, La tch N, et al. CNS effects of a CCR5 inhibitor in HIV -infected 
subjects: a pharmacokinetic and cerebral metabolite study. J Antimicrob Chemother 
2012;67:206 -12. 
 
72. Yilmaz A, Watson V, Else L, Gisslen M . Cerebrospinal fluid maraviroc concentrations in 
HIV-1 infected patients. AIDS 2009;23:2537- 40. 
 
73. Wang L, Soon GH, Seng KY, et al. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers. Antimicrob Agents 
Chemother 2011;55:4090- 5. 
 
 73 A5324 
Final Version 2.0  
  08/25/17  
 
  
74. Weatherley B, McFadyen L. Maraviroc modelling strategy: use  of early phase 1 data to 
support a semi -mechanistic population pharmacokinetic model. Br J Clin Pharmacol 
2009;68:355 -69. 
  A5324 (08/25/17)  
Final Version 2.0  
  Page 1 of 15 
  
APPENDIX I  
 
DIVISION OF AIDS  
AIDS CLINICAL TRIALS GROUP (ACTG)  
SAMPLE INFORMED CONSENT  
 
For protocol A5324  
A Randomized, Double- Blinded, Placebo- Controlled Trial Comparing Antiretrovir al 
Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with 
Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV  
Final  Version 2.0  dated 08/25/17  
 
 
SHORT TITLE FOR THE STUDY:  Integrase and Maraviroc Intensification in Neurocognitive 
Dysfunction (InMIND) , Final  Version 2.0 dated 0 8/25/17  
 
 
INTRODUCTION  
 
You are being asked to take part in this research study because you are infected with the 
human immunodeficiency virus (HIV),  the virus that causes AIDS . This study is sponsored by 
the National Institutes of Health (NIH). The doctor in charge of this study at this site is: (insert name of Principal Investigator). Before you decide if you want to be a part of this study, we  want 
you to know about the study.   
 This is a consent form. It tells you about this study. The study staff will talk with you about this 
information. You are free to ask questions about this study at any time. If you agree to take part 
in this study, you will be asked to sign this consent  form. You will get a copy to keep.  
 
 
WHY IS THIS STUDY BEING DONE?  
 There are now several HIV treatment options for a person with HIV infection who has not yet 
been treated. Most people who receive treatment and take their medications as directed have a good test result. This is usually determined by measuring the amount of HIV in the blood (viral 
load). The best response is when HIV cannot be found ( undetectable) in the blood. However, it 
has recently become clear that some people with HIV who are receiving effective HIV drugs 
continue to have more health problems than people without HIV infection. Sometimes, there is 
damage to organs in the body, including bone, kidneys, and the brain.  
 The reasons this study is being done are the following:  
• To see how the study drug combinations affect your ability to use your fingers and hands, 
concentrate, learn and remember, speak and write, think, solve problems and make decisions . 
• To see how well the study drug combinations lower your HIV viral load.  
• To see how safe  the study drug combinations are, how well people are able to take the 
study drug combinations, and how well their immune systems respond to the study drugs.  
  A5324 (08/25/17)  
Final Version 2.0  
  Page 2 of 15 
 
 • To see how well the study drug combinations get into your blood.  
 
The drugs we are testing in thi s study  are maraviroc (MVC) and dolutegravir (DTG). Both of 
these drugs have been approved by the Food and Drug Administration (FDA) for treatment of 
HIV. MVC  and DTG will be added to your current drug regimen.  
 
Some participants in the study  will not be g iven the drugs that  we are testing. Instead, they will 
be given a placebo. Placebo pills are just pills with no active ingredient in them.  
 You will be given one of the following three drug combinations:  
• Placebo for MVC and placebo for DTG  
OR 
• DTG active drug and placebo for MVC  
OR 
• MVC and DTG active drugs  
 
 
WHAT DO I HAVE TO DO IF I AM IN THIS STUDY? 
 
If you would like to be in this study, after you have read and signed this informed consent form, you will come to the clinic for a screening exam to make sure you meet the requirements for 
joining the study.  
 
At Screening  
This visit will take about 1  to 2 hours.  The tests for this visit may be done in more than one day 
if that will be easier for you. At the screening visit: 
 
• Your  HIV infection status will b e confirmed. If there is no record available, another HIV test  
will be done. You may have to sign a separate consent form before this is done.  
• We will ask you questions  about your medical history, any medications you are taking or 
have taken within the last 30 days, and about the anti- HIV drugs you  are taking  (such as 
how long you have been taking the anti -HIV drugs  you are currently taking,  if you stopped 
taking them for any reason for more than 7 days , etc.) .  
• You will have a physical exam  and will be asked questions about your health.  
• You will have about 1- 2 tablespoons (25mL) of blood drawn to measure your viral load (the 
amount of HIV in your blood), to see if you are infected with the hepatitis C  virus (an 
infection of the liver)  if there is no record available, to see if you have syphilis (a type of 
sexually transmitted disease),  and to have some other routine tests for safety. You will be 
told the results of these tests when they become available.   If the syphilis test shows that 
you have syphilis, your result, by state law, will be forwarded to the    Board of 
Health (sites please modify as appropriate per  your state/local law) .   
• We will ask you to give a urine sample for safety testing. We will give you the results of this 
test as soon as it becomes available.  
• You will be given a liver enzyme test, formerly called liver function test (LFT) to see if you 
have damage to your  liver and if your liver is working well.  
  A5324 (08/25/17)  
Final Version 2.0  
  Page 3 of 15 
 
 • You will be asked some questions about yourself, such age, educational level and prim ary 
language. 
• You will take neuropsychological tests, which will take about 1 hour. During the neuropsychological tests you will answer questions, list items (such as naming foods, or 
animals, or some other groups you know), and do simple tasks. You will b e asked questions 
to see if you forget things, have difficulty understanding facts, or difficulty with your behavior 
and interacting with others.   
− Problems with thinking and decision making are an important effect of HIV -1 infection on 
the brain. These problems are known as neurocognitive impairment, and impact specific 
areas of brain functioning  such as your ability to use your fingers and hands, 
concentrate, learn and remember, speak and write, think, solve problems and make decisions. Neurocognitive impairment  has been classified into diagnoses, HIV 
Associated Neurocognitive Disorders, which is abbreviated as HAND. The diagnosis of 
HAND can go from least to most severe.  
− The study team will determine if you have HAND and are eligible for the study based on  combining the results of the neuropsychological testing, gathering data on 
other conditions that can impact brain functioning and therefore your thinking, and also seeing how these changes in thinking ability have affected your home, social and work 
life. 
• If you are a woman able to become pregnant, we will ask you to give a urine sample or have 
an additional 1 teaspoon (5mL) of blood drawn to see if you are pregnant. You will not be able to enroll in this study if you are pregnant. You will be told the result of the test when it becomes available.   
• You will be asked to complete some questionnaires  that ask about  how you are feeling,  how 
well you are able to perform your daily activities , and about your alcohol and drug use . 
 
At Pre -Entry  
If you are eligible for the study, you will come in for a pre -entry visit. This visit will last about 30  
minutes . At this visit  you will have about 5 tablespoons ( 75 mL) of blood drawn, which will be 
stored for future testing.  
 The screening and pre- entry visits may be on different days or on the same day.  
 
At Study Entry Visit  
If you are eligible for the study, you will come in for an entry visit. This visit will last about 1 hour. 
At this visit:  
 
• You will have a physical exam  and will be asked questions about your health and about any 
medicines you have taken or are taking.    
• You will have about 1- 2 tablespoons (25mL) of blood drawn to measure your viral load, to 
measure your CD4+ cell count (CD4+ cells are cells in your blood that fight infection) , and to 
have some other routine safety tests  including liver enzyme test. You will be told the results 
of these tests when they become available.  
• If you are a woman able to become pregnant, you will have a pregnancy test within 2 days 
before entry  into the study . Pregnant women  cannot enter the study.  
  A5324 (08/25/17)  
Final Version 2.0  
  Page 4 of 15 
 
 • You will have about 5- 6 tablespoons (80 mL) of blood drawn, which will be stored for future 
testing.  
• We will ask you to fill out a questionnaire to see how well you are taking your anti- HIV drugs.  
 
We will randomize you to one of three groups:  
• Group A: placebo for MVC and placebo for DTG  
• Group B: DTG active drug and placebo for MVC  
• Group C: MVC and DTG active drugs  
 
Randomized means that we will assign you by chance to one of three groups. You have an 
equal chance of being assigned to any group, like flipping a coin.  [Sites please modify the 
randomization analogy as appropriate to your local culture].   
 This study is a double- blind study. This means that you and your study staff will not know which 
group we assign you to.  We are doing this research because we do not know which treatment group is best for you.   
 
You will continue taking the anti- HIV drugs  that you are currently taking.  You will also be given 
a combination of MVC, DTG or placebo based on the group that you are randomly assigned to.   
You must start the new medications within three days after you are randomized.  
 
After Entry  
After your entry visit, you will come to the clinic at weeks  2, 4, 12, 24, 48, 72, and 96. These 
study visits will last about 1 to 2 hours, except week 12 which will last about 4  hours. During  
these visits:  
 
• You will have a physical exam, and will be asked questions about your health and about any 
medicines you have taken or are taking, at every visit .  
• You will take neuropsychological tests at w eeks 24, 48, 72 , and 96.  
• We will draw about 2 -7 tablespoons ( 30-105mL) of blood for routine safety tests, to measure 
your viral load, and to measure your CD4+ cell count. You will be told the results of these tests when they  become available. You will have routine safety tests, including liver enzyme 
test, at weeks 4,  12, 24, 48, 72 , and 96; viral lo ad measured at weeks 12, 24, 48 , 72, and 
96; and CD4+ cell count measured at weeks 12, 24, 48, 72 , and 96. We will also store some 
of your blood for future testing at every visit .  
• W e will draw an additional 1 teaspoon- 1 tablespoon (5 -15mL) of blood for pharmacokinetic 
studies (PK) to measure the amount of study drug in your blood at weeks 12, 24 , and 48. At 
these visits we will draw blood before you take the  study  drugs . At week 12 we will also draw 
blood 2 and 4 hours after you take the  study drugs.  If one of the study drugs you will be 
taking are taken in the evening, 3 days before the PK studies at weeks 12, 24, and 48 , 
you will have to switch taking that study drug from the evening to the morning. The study staff will contact you before that time to remind you when to make the switch. 
You must also not take the study drugs in the morning on the day of the weeks 12, 24, 
and 48 visits, and instead bring the study drugs with you to the clinic. The study staff 
will give you the doses in the clinic.  
• We will ask you to give a urine sample at week 96 for safety testing. You will be told 
the result when it is available.  
  A5324 (08/25/17)  
Final Version 2.0  
  Page 5 of 15 
 
 • We will ask you to fill out some questionnaires at weeks 24, 48, 72, and 96 that ask about  
how you are feeling, how well you are able to perform your daily activities,  and your alcohol 
and drug use . We will also ask you to fill out a questionnaire about how well you are taking 
your current anti -HIV drugs  at weeks  4, 12, 24, 48, 72 , and 96.  If you are having problems 
taking your anti -HIV drugs correctly, a site staff mem ber will try to help .  
• If you are a woman and you think you might be pregnant, you will have a pregnancy test. You will be told the result of this test when it becomes available.  
• At weeks 12, 24, 48, and 72, your study drugs will be refilled.  
 
At weeks 36, 60, and 84, you will return for refill of your study drugs. These refills should 
take about 30 minutes or less.  No other evaluations will be done.  
 
You should inform the study doctor before changing the other anti -HIV drugs that you 
are taking.  
 
Optional Lumbar Puncture 
In this study, there is an optional lumbar puncture. A lumbar puncture (also called a “spinal tap”) removes fluid that surrounds the brain and spinal cord.  This is done by numbing a small patch of 
skin on your back and inserting a needle in between the bones in your lower back. You will be asked to lie in a flat position (with one or no pillows) at the clinic  for up to 30 minut es after the 
test. You should also drink plenty of liquids and not do too much activity for up to 24 hours after 
the test . Your clinic may ask that you sign a separate consent form before you have this 
procedure.  
 The lumbar puncture  will be performed to  measure inflammatory markers  (a measure of the 
body’s response to infection or damage) to see if your brain is affected by HIV .  
 
• If you agree to participate in the optional lumbar puncture study, you will have a neurological 
exam at study entry and week 48. The neurological exam will see if you have any nerve damage or nervous system problems and will take about 30 to 45 minutes.  
• If you  had abnormal bleeding or bruising in the past or the study doctor feels you may be at 
risk of having abnormal bleeding, you will also have about 1 teaspoon (6mL) of blood drawn 
to check the number of platelets (the cells in the blood that stop bleeding) in your blood and 
to see how long it takes your blood to clot at study entry  and week 48. You will be told the 
results of the tests when they become available.  
• If you are eligible for the lumbar puncture, you will have a  lumbar puncture at study entry 
and week 48.  About 2 to 3 teaspoons of spinal fluid will be collected for routine and study -
specific tests and HIV viral load.  
 
Please indicate and initial below whether you agree to participate in the optional lumbar 
puncture.  
 
________ YES , I agree                     ________ NO , I disagree  
 
Virologic Failure 
You will be tested for virologic failure at weeks 12, 24, 48 , 72, and 96. Virologic failure is when 
your anti -HIV drugs are not fully suppressing HIV in the blood. If the study staff sees that your 
  A5324 (08/25/17)  
Final Version 2.0  
  Page 6 of 15 
 
 viral load has gone up, you will be asked to have another viral load test done within 30 days.  
About 2 teaspoons (10mL) of blood will be drawn for the viral load test. We will also draw an additional 1-2 teaspoons  (6mL) of blood that will be used for tests that check which anti- HIV 
drugs have stopped working on the HIV in your blood (resistance test) and if a specific type of anti-HIV drug will be able to control your HIV (tropism test) if the repeat viral load test shows 
that your viral load is still up.  We will also ask you to fill out a questionnaire about how well 
you are taking your current anti -HIV drugs. 
 
If your viral load is still up and you are still taking study drug, you will be asked to stop the study 
drug, and come to the clinic within 2 weeks. You will be followed on study and off study 
treatment until the final study visit, week 96.  If you have virologic failure at w eek 96, you will 
have a confirmation of virologic failure within 30 days, and you will be off study.  
After you start your study drugs, you should not stop taking any of them unless you have discussed it with the study doctor. If you do not take your study  drugs or other HIV 
medications consistently, this may result in viral rebound, a condition in which HIV levels in your blood become detectable. This could lead to drug resistance and a chance that 
the study drugs, or your other HIV medications, will no longer be effective. Discontinuing 
HIV medications can also result in immune system decline. If your blood test shows evidence of drug resistance, you will be taken off the study drugs but will be asked to 
continue follow -up in the study until you complete all visits and procedures.  
 Although very unlikely, you could develop viral rebound or drug resistance during this 
study. If drug resistance develops, your choices of HIV medications in the future could be limited.   
 
If You Have to Stop Taking the Study Drugs Early or You Have to Stop the Study Early  
If you have to stop taking the study drugs early or you have to stop the study early, you will come to the clinic for an additional visit.  At this visit: 
 
• You will have a physical exam and will be asked questions about your health and about any 
medicines you have taken or are taking. 
• You will take neuropsychological tests.  
• We will draw about 1 tables poon ( 15mL) of blood to measure your viral load and CD4+ cell 
count. We will tell you the test results of when they  become available.  
• We will draw about 2 tablespoons ( 30mL) of blood and store the blood for future study -
related virologic testing.  
• If you are a woman and you think you might be pregnant, you will have a pregnancy test. We will tell you the test result when it becomes available.  
• We will ask you to fill out some questionnaires to see how you are feeling, how well you are able to perform your daily activities, if you have been hospitalized recently, and how well you are taking your current anti -HIV drugs  
• We will ask you to  give a urine sample for safety testing. We will give you the results of this 
test as soon as it becomes available.  
 
  A5324 (08/25/17)  
Final Version 2.0  
  Page 7 of 15 
 
 If you do not enroll into the study  
If you decide not to take part in this study or if you do not meet the eligibility requirements, we will still use some of your information. As part of this screening visit, some demographic ( age, 
gender, race), clinical (disease condition, diagnosis), and laboratory (CD4 cell count, viral load) information is being collected from you so that  ACTG researchers may help determine whether 
there are patterns or common reasons why people do not join a study.  
Other  
Some of your blood or spinal fluid (if you have a lumbar puncture) that is left over after all required study testing is done may be stored (with usual protectors of identity) and used for 
ACTG -approved HIV -related research. Storage of leftover blood or spinal fluid is not a 
requirement to participate in the study  and you may withdraw your approval for the storage of 
your leftover blood o r spinal fluid at any time, and your samples will be destroyed.  These 
samples may be held for an indefinite length of time. We cannot ensure that you will be told of 
the results of the research done on these samples. Please indicate and initial below whether 
you approve the use of your leftover blood or spinal fluid .  
 
________ YES                     ________  NO 
 
At sites outside the US, biological  specimens may be shipped and stored outside the 
country from which they were collected (e.g. , sites that do not have a central testing 
laboratory in- country  and storage of left -over specimens ). 
  HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY? 
 
About 186 people will take part in this study . 
  HOW LONG WILL I BE IN THIS STUDY?  
 You will be in this study for about 24  months  (2 years) .   
  WHY WOULD THE DOCTOR TAKE ME OFF THIS STUDY EARLY? 
 
The study doctor may need to take you off the study early without your permission if:  
• your primary care physician no longer thinks that participating in the study is in your best interest  
• the study is stopped or cancelled  
• you are not able to attend the study visits  or perf orm the assessments  as required by the 
study  
 
The study doctor may need to take you off the study drugs  without your permission if:  
• you become pregnant  or start br eastfeeding  
• continuing the study drug(s) may be harmful to you 
• you need a treatment that you may not take while on the study  
  A5324 (08/25/17)  
Final Version 2.0  
  Page 8 of 15 
 
 • you are not able to take the study drug(s) as required by the study  
 
If you must stop taking the study drug(s) before the study is over, the study doctor may ask you 
to continue to be part of the study and return for some study visits and procedures.  
 
If I have to permanently stop taking study -provided drugs, or once I leave the study, how would 
they be provided?  
 During the study:  
If you must permanently stop taking study -provided drugs before your study participation is 
over, the study staff will discuss other options that may be of benefit to you.  
After the study:  
After you have completed your study participation, the study will not be able to continue to provide you with the drugs you received on the study. If continuing to take these or similar drugs 
would be of benefit to you, the study staff will discuss how you may be able to obtain them.  
 
WHAT ARE THE RISKS OF THE STUDY?  
 The drugs used in this study may have side effects, some of which are listed below. Please note 
that these lists do not include all the side effects seen with these drugs. These lists include the 
more serious or common side effects. If you have questions concerning the additional study 
drug side effects please ask the medical staff at your site.  
 There is a risk of serious and/or life- threatening side effects when non -study drugs are taken 
with the study drugs. For your safety, you must tell the study doctor or nurse about all drugs you 
are taking (including non -prescription drugs, vitamins and herbal supplements)  before you start 
the study and also before starting any new drugs while on the study. You must also tell the 
study doctor or nurse before enrolling in any other clinical trials while on this study.  
 
Use of Combination Antiretroviral Drugs  
Immune Reconstitution Syndrome:  
In some people with advanced HIV infection, symptoms from other infections or certain diseases may occur soon after starting combination anti -HIV treatment but can also 
occur later. Some of these symptoms may be life- threatening. If you start having new 
symptoms, or notice that existing symptoms are getting worse after starting your antiretroviral therapy, tell your healthcare provider right away.  
 The use of potent antiretroviral drug combinations may be associated with an abnormal 
placement of body fat and wasting. Some of the body changes include:  
• Increase in fat around the waist and stomach area 
• Increase in fat on the back of the neck 
• Thinning of the face, legs, and arms  
• Breast enlargement  
 
  A5324 (08/25/17)  
Final Version 2.0  
  Page 9 of 15 
 
 Risks of Social Harm  
Although the study site will make every effort to protect your privacy and confidentiality, it is possible that other people could find out that you are in a study and this could cause problems 
for you. For example, other people might figure out that you are infected with HIV. If this 
happens, people could treat you unfairly or family members, friends, and/or the community 
might not accept you.  
 
Risks of Drawing Blood  
Taking blood may cause some discomfort, lightheadedness, bleeding, swelling, or bruising 
where the needle enters the body, and in rare cases, fainting, or infection.  
 
Risk of Spinal Tap  
• Leakage of cerebrospinal fluid ( CSF) into the tissues in your back, which can cause 
headache  
• Back pain or pain where the needle is inserted in the back   
• Decreased blood pressure 
• CSF leak  
• Infection 
• Fever  
• Nerve injury (very rare)  
• Bleeding  
• Allergic reaction to medication used to numb the area where the spinal tap will be done.   
• Allergic reaction to the substance (such as iodine) that is used to clean the area of the spinal 
tap to prevent infection could include itching, hives, swelling, shortness of breath, difficulty 
breathing, changes in blood pressure and heart rhythm, loss of consciousness, or in a rare 
case, death.  
 
Headaches can be helped by lying down face up and by taking over -the-counter headache 
medicine. Severe headaches should be reported to the study staff or study doctor . 
 
It may be uncomfortable for you to lie on your side while the lumbar puncture is being done and 
to lie flat on your back for the required time afterwards.  
Risks of 
MVC ( Selzentry ) 
The following serious side effects have been associated with the use of MVC :  
 
Liver problems (liver toxicity) have occurred in people who took MVC . An allergic reaction may 
happen before liver problems occur. Stop taking MVC and call the study doctor  or your 
healthcare provider  right away if you get any of the following signs or symptoms:  
• Rash on your body (allergic reaction)  
• Yellowing of the skin or whites of your eyes  (jaundice)  
• Dark urine  
• Vomiting  
• Stomach pain 
• Elevated liver-related function test  – People who are co -infected with hepatitis B might be at 
higher risk of having liver problems.  
  A5324 (08/25/17)  
Final Version 2.0  
  Page 10 of 15 
 
  Heart problems, including heart  attack . 
 
Low blood pressure when standing up, which can  cause dizziness or fainting.  People who have 
serious kidney problems may be at increased risk for dizziness and fainting.   
 
In addition to the serious side effects listed above, additional side effects include:  
• Colds  
• Cough 
• Fever  
• Rash  
• Dizziness  
• Diarrhea 
• Swelling of parts of the body  
• Flu and flu- like symptoms 
• Muscle aches, spasms and pain  
• Stomach  pain and bloating 
• Sleeping problems  
• Runny, congested nose  
• Problems with urination 
• Low amounts of white b lood cell counts (neutropenia)  
 NOTE : Because of how the drug works in your body, there is a possible increased risk for 
getting other infections or cancer, although there is no evidence from the clinical trials of an 
increase in serious infections or canc er. 
 MVC  contains soy lecithin. If you have a medical history of allergy to soy (soya or soybeans) or 
peanuts, you may develop an allergic reaction to MVC . Before starting MVC , you should inform 
the study staff or study doctor  if you are allergic to soy or  peanuts.  
 
Risks of DTG  (Tivicay ) 
The following serious side effects have been associated with the use of DTG . These include 
allergic reactions and liver problems, which may be life- threatening.  
 
Contact  the study doctor  or your healthcare provider  right away if you develop a rash while 
taking  DTG , especially if it i s associated with any of the symptoms listed below . Stop 
taking DTG  and get  medical help right away if you develop a rash with any of the following 
signs or symptoms :  
• Fever 
• Generally ill feeling 
• Extreme tiredness  
• Muscle or joint aches  
• Blisters or sores in mouth 
• Blisters or peeling of the skin 
• Redness or swelling of the eyes  
• Swelling of the mouth, face, lips, or tongue  
  A5324 (08/25/17)  
Final Version 2.0  
  Page 11 of 15 
 
 • Problems breathing  
 
Contact the study doctor or your healthcare provider if you have any of the following 
symptoms that could be signs of liver problems:   
• Yellowing of the skin or whites of the eyes  
• Dark or tea- colored urine  
• Pale-colored stools or bowel movements  
• Nausea or vomiting 
• Loss of appetite  
• Pain, aching, or tenderness on the right side below the ribs  
 
People with a pre-existing history of depression or other mental health illness may be at 
greater risk for suicidal thoughts, or attempts, which may lead to death. If your mental 
health illness worsens, or if you develop suicidal thoughts, call the study doctor or your 
healthcare provider right away.  
 
Other  side effects of DTG  include:  
• Changes in liver test results, more common in people with hepatitis B or C  
• Trouble sleeping 
• Tiredness  
• Headache 
 
Tell the study doctor  or your healthcare provider  about any side effect that bothers you or that 
does not go away.  
 
 
ARE THERE RISKS RELATED TO PREGNANCY?  
 The drugs used in this study may be unsafe for unborn babies. If you are having sex that could lead to pregnancy, you must agree not to become pregnant. Because of the risk involved, you 
must use at least one method of birth control. You must continue to use birth control for  6 weeks 
after stopping your medicines. You must choose one of the birth control methods listed below:  
• Condoms ( male or female) with or without a spermicidal agent  
• Diaphragm or cervical cap with spermicide  
• Intrauterine device (IUD)  
• Hormone- based contraceptive 
 
If you can become pregnant, you must have a pregnancy test before you enter this study. The 
test must show that you are not pregnant. If you think you may be pregnant at any time during 
the study, tell your study staff right away. If you are pregnant  you will be taken off the study 
treatment , but asked to continue the study evaluations. The study staff will talk to you about 
your choices.  
 
If you become pregnant while on study, the study staff would like to obtain information from you 
about the outcome of the pregnancy (even if it is after your participation in the study ends). If 
you are taking anti -HIV drugs when you become pregnant, your pregnancy will be reported to 
  A5324 (08/25/17)  
Final Version 2.0  
  Page 12 of 15 
 
 an international database that collects information about pregnancies in women taking anti -HIV 
drugs. This report will not use your name or other information that  could be used to identify you.  
 
NOTE: It is not known whether the study drug  passes through breast -milk and may cause harm 
to your baby. If you are breastfeeding, you cannot take part in this study.  
 
 ARE THERE BENEFITS TO TAKING PART IN THIS STUDY?  
 If you take part in this study, there may be a direct benefit to you, but no guarantee can be 
made. It is also possible that you may receive no benefit from being in this study. Information 
learned from this study may help others who have HIV.  
  WHAT OTHER CHOICES DO I HAVE BESIDES THIS STUD Y? 
 Instead of being in this study you have the choice of: 
• treatment with prescription drugs available to you  
• treatment with experimental drugs, if you qualify  
• no treatment  
 
Please talk to your health care provider about these and other choices available to you. Your 
health care provider will explain the risks and benefits of these choices.  
  WHAT ABOUT CONFIDENTIALITY?  
 
For Sites in the US  
We will do everything we can to protect your privacy. In addition to the efforts of the study staff to help keep your  personal information private, we have applied for/obtained a Certificate of 
Confidentiality from the U.S. Federal Government. This certificate means that researchers 
cannot be forced to tell people who are not connected with this study, such as the court system, 
about your participation. Also, any publication of this study will not use your name or identify you personally.   
 People who may review your records include the ACTG, Office for Human Research Protections 
or other government agencies as part of their duties, Food and Drug Administration (FDA),  
(insert name of site) Institutional Review Board (a group that protects the rights and well -being 
of people in research), National Institutes of Health (NIH), study staff, study monitors, the drug 
company  supporting this study, and its designees. Having a Certificate of Confidentiality does 
not prevent you from releasing information about yourself and your participation in the study.  
 Even with the Certificate of Confidentiality, if the study staff learns of possible child abuse or 
neglect or a risk of harm to yourself or others, we will be required to tell the proper authorities.  
 
  A5324 (08/25/17)  
Final Version 2.0  
  Page 13 of 15 
 
 A description of this clinical trial will be available on ClinicalTrials.gov as required by U.S. Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time . 
 
For Sites outside the US  
Efforts will be made to keep your personal information confidential. We cannot guarantee absolute confidentiality. Your personal information may be disclosed if required by law. Any publication of this study will not use your name or identify you personally.  
 
Your records may be reviewed by the ACTG, OHRP, FDA, (insert name of site)  IRB, 
National  Institutes of Health (NIH), study staff, study monitors, and drug company  
supporting this study.  
 A description of this clinical trial will be available on www.ClinicalTrials.gov
, as required 
by US law. This website will not include information that can identify you. At most, the 
Web site will include a summary of the results. You can search this Web site at any time.  
 
 
WHAT ARE THE COSTS TO ME?  
 
Taking part in this study may lead to added costs to you and your insurance company. In some 
cases it is possible that your insurance company will not pay for these costs because you are taking part in a research study.   
 
 
WILL I RECEIVE ANY PAYMENT?  
 [Sites please indicate whether you will provide payment to participants]  
 
 
WHAT HAPPENS IF I AM INJURED?  
 If you are injured as a result of being in this study, you will be given immediate treatment for 
your injuries. The cost for this treatment will be charged to you or your insurance company. There is no program for compensation either through this institution or the National Institutes of 
Health. You will not be giving up any of your legal rights by signing this consent form.  
  
WHAT ARE MY RIGHTS AS A RESEARCH PARTICIPANT ? 
 Taking part in this study is completely voluntary. You may choose not to take part in this study or leave this study at any time. Your decision will not have any impact on your participation in 
other studies conducted by NIH and will not result in any penalty or loss of benefits to which you 
are otherwise entitled.  
 
  A5324 (08/25/17)  
Final Version 2.0  
  Page 14 of 15 
 
 We will tell you about new information from this or other studies that may affect your health, welfare, or willingness to stay in this study. If you want the results of the study, let the study staff know.  
  
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS?  
 
For questions about this study or a research -related injury, contact:  
• name of the investigator or other study staff  
• telephone number of above  
 
For questions about your rights as a research participant , contact:  
• name or title of person on the  Institutional Review Board (IRB) or other organization 
appropriate for the site  
• telephone number of above
  A5324 (08/25/17)  
Final Version 2.0  
  Page 15 of 15 
 
 SIGNATURE PAGE  
 If you have read this consent form (or had it explained to you), all your questions have been 
answered and you agree to take part in this study, please sign your name below.  
  
 ____________________________ _________________________________________ 
Participant’s Name (print)  Participant’s Signature and Date  
 
 
____________________________ ________________________________________ 
Participant’s Legally Authorized  Legally Authorized Representative’s Signature  
Representative (print)  and Date  
(As appropriate)  
  
____________________________ _________________________________________ 
Study Staff Conducting Study Staff’s Signature and Date  
Consent Discussion (print)   
 
____________________________ _________________________________________ 
Witness’s Name (print)  Witness’s Signature and Date 
(As appropriate)  
 